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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
  
1.1 EXTENDED RELEASE DRUG THERAPY 
 For many decades treatment of acute diseases or chronic illnesses have been 
mostly accomplished by delivery of drugs to patients using various pharmaceutical 
dosage forms including tablets, capsules, suppositories, creams, ointments, liquids, 
aerosols and injectables. Even today these conventional dosage forms are the 
primary pharmaceutical vehicles commonly seen in the prescription and over the 
counter drug market. The oral conventional types of drug delivery systems are 
known to provide a prompt release of the drug. Therefore to achieve as well as to 
maintain the drug concentration within the therapeutically effective range needed for 
treatment, it is often necessary to take this type of drug delivery system several 
times a day. This results in a significant fluctuation in drug levels often with a sub-
therapeutic and or toxic levels and wastage of drug. Recently several technical 
advancements have resulted in the development of new systems of drug delivery 
capable of controlling the rate of drug delivery, sustaining the duration of 
therapeutic activity and targeting the delivery of drug to a tissue
1
.  
  
 Fig-1:  plasma level versus time profile showing difference between controlled release, 
sustained release and release from conventional dosage form. 
   The term controlled\extended release implies a system that provides continuous 
delivery of the drug for a predetermined period with predictable and reproducible 
kinetics and a known mechanism of release. This means that the release of drug 
ingredient(s) from a controlled release drug delivery system proceeds at a rate that is 
not only predictable kinetically but also reproducible from one unit to another. In 
other words, the system attempts to control drug concentration in the target tissue.   
 The oral route of administration for extended release systems has received 
greater attention because of more flexibility in dosage form design. The design of 
oral extended release delivery systems is subjected to several interrelated variables 
of considerable importance such as type of delivery system, the disease being 
treated, the patient, the length of therapy and the properties of the drug. 
               Extended release
2
denotes that the system is able to provide some actual 
therapeutic control whether be it of temporal or spatial nature or both. In other 
words, the system attempts to provide a constant drug concentration in the target 
tissue. It is this nature of this system that makes it different from sustained release 
systems. 
1.1.1 Advantages of extended release dosage form:3 
 Improved patient compliance and convenience due to less frequent drug      
administration. 
 Reduction in fluctuation in steady state levels and therefore, better control 
of disease condition and reduction intensity of local or systemic side effects. 
 Increased safety margin of high potency drugs due to better control of 
plasma levels. 
 Maximum utilization of drug enabling reduction in total amount of dose 
administered. 
 Reduction in health care costs through improved therapy, shorter treatment 
period, less frequent dosing and reduction in personnel time to dispense, 
administer and monitor patients. 
 Sustained blood levels; the size and frequency of dosing are determined by 
the pharmacokinetic and pharmacodynamic property of drug. The use of 
extended releaseproducts may maintain therapeutic concentration over 
prolonged period. 
 Attenuation of adverse effect, the use of extended release products avoids 
the high initial   blood concentration, which may cause many side effects like 
nausea, local irritation, haemodynamic changes etc.  
 
   1.1.2 Disadvantages of Extended release dosage form:
 3
 
 Toxicity due to dose dumping. 
 Increased cost. 
 Unpredictable and often poor in vitro- in vivo correlation. 
 Risk of side effects or toxicity upon fast release of contained drug 
(mechanical failure, chewing or masticating, alcohol intake). 
 Local irritation or damage of epithelial lining (lodging of dosage forms). 
 Need for additional patient education and counseling. 
 Increased potential for first- pass clearance. 
 
1.1.3 Ideal candidate for extended/controlled release drug delivery 
systems:
 4-6 
              The desired biopharmaceutical characteristics of drugs to be used in the 
development    of per oral CR dosage forms are:  
Molecular weight   :    <1000 Mg  
Solubility                :    0.1 Mcg/ ml 
P
ka
  :     >0.1% to 1% at pH 1 to 7.8 
Apparent partition coefficient :   0.5 to 2.0  
General absorbability   :   From all GI segments  
Stability    :   Stable in GI environment  
 Release should  not  be  influenced  by  pH  and   enzymes. 
Less protein binding  
 To evaluate whether a drug is viable candidate or not for the design of per 
oral CR                                           formulation, one must consider the following 
pharmacokinetic parameters of the drug.  
 
Elimination half-life                :      Preferably between 0.5& 8 hours  
Total body clearance                :      Should not be dose dependent  
Elimination – rate constant       :      Required for the design  
Absolute bioavailability            :      Should be 75% or more  
Absorption rate               :      Must be greater than release rate  
Therapeutic concentration   :                   
The lower the Css
av
 and the smaller the Vd  the lesser is the amount required. 
Apparent volume of distribution (Vd): 
 The larger the Vd and MEC, the larger will be the dose size required. The 
maximum dose to be incorporated in to a per oral CR formulations is about 
500 mg.     The smaller the Vd, the easier is incorporation of drug in to 
dosage form.  
Minimum toxic concentration (MTC):       
       MTC and MEC, the further apart of   these t values are, the safer the 
dosage and also suitable for drugs with very short t
1/2 
1.1.4 Factors influencing oral extended release dosage design: 
            1.1.4.1   Biological Factors: 
    Biological Half Life: 
                 The usual goal of an oral extended –release product is to maintain 
therapeutic blood levels over an extended period. To achieve this, drug must enter 
the circulation at approximately the same rate at which it is eliminated. The 
elimination rate is quantitatively described by half-life t
1/2
. Each drug has its own 
characteristic elimination rate, which is the sum of all elimination process, including 
metabolism, urinary excretion and all other process that permanently remove drug 
from the bloodstream. 
Therapeutic compounds with short half-lives are excellent candidates for 
sustained release preparation, since this can reduce dosing frequency. However this 
is limited. In general, drugs with half-lives shorter than 2hrs, such as furosemide or 
levodopa
7
are poor candidates for sustained release preparations. Compounds with 
long half-lives, more than 8hrs are also generally not used in sustained release 
forms, since their effect is already sustained. dig toxin, wayfaring,  phenytoin
8 
are 
some examples.  
  Absorption 
  The characteristics of absorption of a drug can greatly affect its suitability as 
a extended-release product. Since the purpose of forming an extended-release 
product is to place control on the delivery system, it is necessary that the rate of 
release is much slower than the rate of absorption. If we assume that the transit time 
of most drugs and devices in the absorptive areas of GI tract is about 8-12hrs, the 
maximum half-life for absorption should be approximately 3-4hrs; otherwise, the 
device will pass out of the potential regions before absorption is complete
9
. If a drug 
is absorbed by active transport or transport is limited to a specific region of the 
intestine, sustained release preparations may be disadvantageous to absorption.  
Absorption of ferrous sulphate is maximal in the upper jejunum and 
duodenum and sustained-release mechanisms that do not release drug before passing 
out of this region are not beneficial
10
. It is observed that co administration of food 
results in a sustaining effect
11 
although administration of food can create highly 
variable effects, there have been methods devised to circumvent this problem. One 
such attempt is to formulate low-density pellets, capsules
12
tablets
13
. These float on 
the top of the gastric juice, delaying their transfer out of the stomach
14
. The increase 
in gastric retention results in higher blood levels for P-amino benzoic acid, a drug 
with a limited GI absorption range
15
, but the drugs that have widespread absorption 
in the intestinal system would likely not benefit from an increase in emptying time
16 
. 
  Another approach is that of bio adhesive materials. The principle is to 
administer a device with adhesive polymers having an affinity for the gastric 
surface, most probably the mucin coat
17
. Bio adhesives have demonstrated utility in 
the mouth, eye and vagina.  
 
 
 Metabolism 
         Drugs that are significantly metabolized before absorption, either in the lumen 
or the tissue of the intestine can show decreased bioavailability from slower 
releasing dosage forms. For example, aloprenolol was more extensively metabolized 
in the intestinal wall when given as a sustained-release preparation
18
.High 
concentrations of dopa-decarboxylase  in the intestinal wall will result in a similar 
effect for levodopa
19
. If levodopa is formulated in a dosage form with a drug 
compound that can inhibit the dopa-carboxylase enzyme, the amount of levodopa 
available for absorption increases and can sustain its therapeutic effects. 
Formulation of these enzymatically susceptible compounds as prodrugs is another 
viable solution.  
1.1.4.2 Physicochemical Factors Influencing Oral Extended-Release 
Dosage Form Design  
  Dose size 
For orally administered system, there is an upper limit to the bulk size of the 
dose to be administered. In general, a single dose of 0.5-1.0 gm is considered 
maximal for the conventional dosage form
20
. This also holds for sustained-release 
dosage form, those compounds that require a large dosing size can sometimes can be 
given in multiple amounts or formulated into liquid systems. Another consideration 
is the margin of safety involved in administration of large amounts of drug with 
narrow therapeutic range. 
  Ionization, pKa and Aqueous Solubility 
Most drugs are weak acids or bases. Since the unchanged form of drug 
preferentially permeates across lipid membrane, the drug in an unchanged form is 
advantageous for drug permeation. Consider a drug for which the highest solubility 
is in the stomach and is unchanged in the intestine. For conventional dosage forms, 
the drug can generally fully dissolve in the stomach and then be absorbed in the 
alkaline pH of intestine. For dissolution or diffusion sustaining forms, much of the 
drug will arrive in the small intestine in solid form, meaning that the solubility of the 
drug may change several orders of magnitude during its release. 
  Compounds with very low solubility (<0.01 mg/ ml) are inherently sustained. 
The drugs that are limited in absorption by the dissolution rate are digoxin
21
, 
griseofulvin
22
and salicylamide
23
. The lower limit has been reported to be 0.1 mg/ 
ml
24
. 
  Partition coefficient 
When a drug is administered to the GI tract, it must cross a variety of 
biological membranes to produce a therapeutic effect these membranes are lipid in 
nature therefore, the partition coefficient of oil-soluble drugs becomes important in 
determining the effectiveness of membrane barrier penetration. Partition coefficient 
is generally defined as the ratio of the fraction of drug in an oil phase to that of an 
adjacent aqueous phase. Compounds with a relatively high partition coefficient are 
predominantly lipid soluble and consequently, have very low aqueous solubility. 
Phenothiazine‟s are representative of this type of compound25              
 Stability 
 Orally administered drugs can be subject to both acid-base hydrolysis and 
enzymatic degradation. For drugs that are unstable in the stomach, systems prolong 
delivery over the entire course of transit in the GI tract are beneficial. Compounds 
that are unstable in the small intestine may demonstrate decreased bioavailability 
when administered from a sustaining dosage form. This is because more drug is 
delivered in the small intestine and hence it is subject to degradation. 
Propantheline
26
 and probanthine
26
 are representative examples of such drugs.  
Unsuitable candidates for extended-Release dosage forms
28
:    
Short elimination biological half-life        
E.g.  Penicillin G, Furosemide   
Long elimination biological half life (>12hrs)       
E.g.  Diazepam, Phenytoin 
Narrow therapeutic index           
E.g.Phenobarbital, Digitoxin. 
Not effectively absorbed in the lower intestine.      
 
E.g.  Riboflavin, Ferrous salts.  
No clear advantage for sustained release formulation                                                       
E.g.Griseofulvin. 
Large doses (>1g) 
E.g.Sulphonamides. 
1.1.5 Methods to retard the drug release 
Combining the classification methodology used by Carmella et al and 
controlled release products can be classified as follows: 
 Reservoir systems  including  
       Enteric coated tablets, capsules, coated granules and microcapsules. 
 Osmotic systems. 
 Ion-exchange resins. 
 Matrix systems. 
1.1.6 Mechanism of drug release in extended release systems  
The different mechanisms of drug release in controlled release systems are:
 
 
1. Dissolution-controlled release 
2. Osmotically controlled release 
3. Diffusion-controlled release 
4. Erosion controlled release 
5. Miscellaneous controlled release 
1. Dissolution-controlled release:  
 In extended-release formulations employing dissolution as the rate-limiting 
step, drug release is controlled by dissolution of a polymer. Individual particles or 
granules containing a drug can be unifor mly dispersed in the matrix or coated with 
varying thicknesses of coating material resulting in dissolution and release of the 
drug over extended periods of time. If the dissolution process is assumed to be 
diffusion-layer controlled, in which the rate of diffusion from the solid surface to the 
bulk solution is rate-limiting, the flux is the product of the diffusion coefficient and 
the concentration gradient from the solid surface to the bulk solution side. Flux can 
also be defined as the flow rate of material through a unit area. With encapsulated 
dissolution control, the drug may be coated with slowly dissolving polymeric 
materials. Once the polymeric membrane has dissolved, the entire drug inside the 
membrane is immediately available for dissolution and absorption. Thus, drug 
release can be controlled by adjusting the thickness and the dissolution rate of the 
polymeric membrane. 
2. Osmotically Controlled Systems 
 In addition to the mechanism of solution diffusion, drug release from a 
membrane-reservoir device can also take place through a membrane via an osmotic 
pumping mechanism. In this case, a semi permeable membrane, such as cellulose 
acetate, is utilized to regulate osmotic permeation of water. With constant reservoir 
volume, this type of device delivers a volume of drug solution equal to the volume 
of osmotic water uptake within any given time interval. The rate of osmotic water 
influx, and therefore the rate of drug delivery by the system, will be constant as long 
as a constant thermodynamic activity gradient is maintained across the membrane. 
Such an osmotic delivery system is capable of providing not only a prolonged zero-
order release, but also a delivery rate much higher than that achievable by the 
solution-diffusion mechanism. Osmotic ally controlled release is also applicable to 
drugs with a wide range of molecular weight and chemical composition, which are 
normally difficult to deliver by the solution-diffusion mechanism. 
3. Diffusion Controlled Systems 
 The most commonly used type of membrane material in drug delivery 
systems is homogeneous films of amorphous and semi crystalline polymers above 
their glass transition temperatures. Drug transport occurs by dissolution in the 
membrane at one interface, followed by diffusion down a concentration gradient 
across the membrane and, finally, release from the second interface into the external 
medium. The rate of drug permeation through solution-diffusion membranes is 
directly proportional to the product of the drug-diffusion coefficient in the polymer 
and the polymer/solution partition coefficient. In diffusion-controlled release 
systems, the transport of solute through the polymer is achieved by molecular 
diffusion due to concentration gradients. Depending on the molecular structure of 
the polymer, these systems may be classified as porous or nonporous. Porous 
controlled-release systems contain pores of large enough size so that diffusion of the 
solute is accomplished through water, which has filled the pores of the polymer. 
In reservoir (membrane) systems, the bioactive agent is usually enclosed at 
relatively high concentrations between two semi permeable membranes and placed 
in contact with a dissolution medium (water or other biological fluid). 
In matrix (monolithic) systems, the bioactive agent is incorporated in the polymer 
phase either in dissolved or in dispersed form. Therefore, the solubility of the solute 
in the polymer becomes a controlling factor in the mathematical modeling of these 
systems. 
4. Erosion controlled release 
Chemically controlled systems include all polymeric formulations in which solute 
diffusion is controlled by a chemical reaction, such as the dissolution of the polymer 
matrix or cleavage of the drug from a polymer backbone. In most chemically 
controlled systems, solute release is controlled by the geometric shape of the device. 
Depending on the type of degradation reaction, these systems may be classified as 
chemically degradable (e.g., by hydrolysis) or biodegradable (e.g., by enzymatic 
reaction) controlled-release systems. 
5. Miscellaneous forms of controlled release 
Ion-exchange resins 
Altered density: Drug-coated micro pellets 
pH-independent formulations 
Barrier coating 
Embedment in slowly eroding matrix Embedment in plastic matrix Repeat action 
         
Fig. 2: Schematic representation of dissolution from different types of delivery 
systems 
 
 
Fig.3 : Schematic representation of plasma profiles from different types of 
delivery systems 
IR:Immediate release, ER:Extended release, DR:Delayed release 
  
Table1. CLASSIFICATION OF ORAL CONTROLLED RELEASE 
SYSTEMS: 
TYPE OF SYSTEM RATE CONTROLLING MECHANISM 
Diffusion Controlled 
 Reservoir system 
 Monolithic system 
Water permeation controlled 
 Osmotic systems 
 Swelling systems 
Chemically Controlled 
 Monolithic system 
 
 Pendent systems 
 
 Ion exchange resins 
Regulated systems 
 Magnetic, Ultrasound 
 
 Chemical 
 
 
 
 
Diffusion through a membrane 
 
 
Osmotic transport of water through a semi 
permeable membrane 
Water penetration into a glassy polymer 
Either pure polymer erosion (surface erosion) 
or a combination of erosion and 
diffusion(bulk erosion) 
 
Combination of hydrolysis of the pendent 
group and diffusion from the bulk polymer 
Exchange of acidic or basic drugs with ions 
present on resins 
External application of magnetic field or 
ultrasound device 
Use of competitive desorption or enzyme 
substrate reactions. Rate control is built into 
the device. 
 1.1.7 Regulatory considerations in extended release products
27
: 
  The drug product meets the controlled release claims made for it. 
 The bioavailability profile established for the drug product rules out the 
possibility of any dose dumping. 
 The drug product‟s steady-state performance is equivalent to a currently 
marketed non-controlled release or controlled release drug product with the 
same active ingredient or therapeutic moiety, which has been subjected to an 
approved full new drug application. 
 The drug product‟s formulation provides consistent pharmacokinetic 
performance between administrations. 
 The reference standard for comparative studies should include one of the 
following 
 A solution or suspension of the same active drug ingredient or therapeutic 
moiety. 
 A currently marketed approved non-controlled release drug product 
containing the same active drug ingredient or therapeutic moiety. 
 A currently marketed controlled release drug product subject to an approved 
full new drug application containing the same active drug ingredient or 
therapeutic moiety. 
 
1.2  MATRIX FORMULATION:
 27-29 
1.2.1    Definition: 
Matrix formulations are defined as a drug or other active ingredient 
embedded in insoluble excipient in order to achieve release by a continuous 
leaching of the drug from the inert matrix core. 
 
1.2.2 Classification: 
        Matrix systems can be divided into three types:   
 Monolithic matrix tablets.     
  
 Gel forming hydrophilic matrix tablets.   
  
 Erodible (hydrophobic) matrix tablets. 
 
 
 
 Inert monolithic matrix tablets:28 
        Probably the simplest method of obtaining sustained release of a drug from 
an oral dosage form is incorporation of a drug in an inert matrix. In this inert means 
non-interacting with the biological fluids. The main reason for its popularity is that 
drug release from plastic matrix tablets is independent on the state and condition of 
the digestive juices, which may show large inter- and intra-patient variability (pH, 
viscosity). 
    During its transit through the gastro-intestinal tract, the porous matrix tablet 
does not disintegrate like conventional tablets, but remains intact and the skeleton 
can be recovered in feces. The materials used in the preparation of these inert 
matrices are predominantly (insoluble) polymers and lipophilic compounds. The 
first polymers to be used for the preparation of matrix tablets were (semi) synthetic 
polymers such as polyethylene, polyvinyl chloride, polymethyl methacrylate, 
polystyrene, poly vinyl acetate, cellulose acetate and ethyl cellulose. The fat 
compounds used included carnauba wax, hydrogenated castor oil, and tristearin. 
      Major drawback of most of the inert polymeric matrix tablets were their 
inherent first order drug release characteristics, their poor direct compression 
characteristics and the problematic cleaning of agglomeration equipment used for 
the preparation of agglomerates with the required compression characteristics. 
Mechanism of release of inert monolithic matrix tablets: 
29 
        Release from inert matrix tablets occurs via a leaching mechanism. Drug 
particles dispersed in the polymer matrix dissolve in the penetrating gastro-
intestinal fluids and are released from the tablet by diffusion through the porous 
network of already existing pores and pores that are created by dissolution of the 
drug particles. At drug loadings exceeding approximately 10-15 volume %, a 
continuous structure connecting all drug particles exists (percolating drug network). 
At considerably lower loadings, a particular fraction of the drug may be completely 
surrounded by the polymer matrix (trapped fraction), which would result in 
incomplete release. 
 
Fig .4: Schematically representation of a leaching-based release mechanism. 
 Solvent activated matrix tablets: 
The use of solvent activated matrix tablets as a method to obtain zero order release i.e. 
constant release rates over an extended period was first proposed by Hopfenberg. Solvent-
activated drug delivery system is a collective term comprising those systems in which the 
interaction between polymer and water is responsible for achieving controlled release. The 
interaction with water may include plasticization, swelling, dissolution, erosion or 
degradation of the polymer. The two most important types of solvent activated matrix 
tablets are gel-forming hydrophilic matrix tablets and erodible (hydrophobic) matrix 
tablets. 
 Gel-forming hydrophilic matrix tablets: 
   Gel-forming hydrophilic or swell able matrix systems are homogeneous or 
heterogeneous systems in which the drug is dispersed in a swell able hydrophilic 
polymer. These systems have been widely studied by researchers since they offer 
the possibility to obtain a constant drug delivery over an extended period of time. 
Drug release is a function of the polymer characteristics. 
 Upon swallowing gel-forming hydrophilic matrix tablets, the hydrophilic 
polymer is plasticized by the aqueous gastro-intestinal due to which undergoes 
macromolecular chain relaxation and volume expansion. Consequently, upon 
penetration of the gastro-intestinal fluids into tablet, a sharp front can be 
distinguished which separates a dry, glassy core from a hydrated and rubbery gel 
layer. Release is governed by diffusion of the dissolved drug through the swollen 
gel layer and generally shows a burst effect, caused by dissolution and leaching of 
drug particles present at the surface prior to formation of the release-controlling gel. 
The mechanism of drug release from swell able devices is determined by the 
relative position of the rubber-glass interface, the rate at which it penetrates the 
tablet, the diffusion coefficient of the drug and the erosion rate of the gel. When the 
penetration rate is high as compared to the drug diffusion rate through the swollen 
gel layer, release is controlled by the diffusion rate of the drug through the gel layer 
and a diffusion controlled (Fickian) release mechanism is observed. If diffusion of 
drug through the gel layer is fast as compared to the water penetration rate, release 
of the incorporated drug is governed by the penetration rate of the interface and 
zero-order drug release with constant release rate may be achieved. Several 
dimensionless parameters have been developed to characterize drug release from 
swelling controlled dosage forms. The Deborah number (De) represents the ratio of 
the characteristic relaxation time of the swelling polymer () relative to the 
characteristic diffusion time of the water into the polymer () 6, 7. The swelling 
interface number (Sw) represents the ratio of the solvent penetration front velocity 
() to the rate of drug diffusion through the swollen polymer: 
                           De =  / Sw =.(t)  / ID 
Where ID is the diffusion coefficient of the drug in the swollen layer and (t) is 
the thickness of the latter. In order to characterize release behavior, it is necessary 
to determine both De and Sw since neither of these values is sufficient by itself. 
Pappas and co-workers have extensively investigated diffusion and solvent 
controlled drug release from swell able polymeric devices with various geometries. 
Release from swell able tablets can easily be analyzed by the following simple 
equation: 
                                        Mt / M= kt
n
 
Where Mt / M are the fractional drug release, k is a constant representing 
structural and geometrical characteristic of the device, and n gives the type of 
release mechanism. 
When the rate at which the penetration front moves inward into the glassy core is 
high as compared to the diffusion rate of dissolved drug molecules through the 
swollen gel layer, release is controlled by the diffusion rate of the drug through the 
gel layer and a Fickian diffusion controlled release mechanism with n  0.5 is 
observed. If diffusion of the drug through the gel layer is fast as compared to the 
solvent penetration rate, release of the incorporated drug is governed by the 
penetration rate of the interface. For dosage forms with slab geometry, this leads to 
zero-order release (n=1), which is also called non-Fickian, case II or solvent 
penetration controlled release. Release profiles with intermediate n-values (0.5 < n 
<1) are classified as anomalous.
30 
       Other swell able polymers, which have been applied in swelling-controlled 
oral drug delivery systems, which show solvent controlled release, are guar gums, 
poly (ethylene oxide) (PEO), poly (vinyl alcohol), ethylene-vinyl alcohol 
copolymers (EVA) and dextran‟s. 
 Erodible matrix tablets: 
        Erodible polymers such as poly anhydrides offer another interesting material 
platform for zero-order drug release. Like several HPMC grades, upon water 
penetration, poly anhydrides form a gel-layer, which erodes at a specific rate. By 
choosing the right polymer composition the thickness of the gel-layer may remain 
constant with time resulting in a constant release rate until depletion of the drug
.
 
In the last two decades, controlled release dosage forms have made significant 
progress in terms of clinical efficacy and patient compliance. Preparation of drug-
embedded matrix tablet that involves the direct compression of a blend of drug, 
retardant material and additives is one of the least complicated approaches for 
delivering drug in a temporal pattern into the systemic circulation. The matrix 
system is commonly used for manufacturing controlled release dosage forms 
because it makes such manufacturing easy. A wide array of polymers has been 
employed as drug retarding agents each of which presents a different approach to the 
matrix concept. Polymers forming insoluble or skeleton matrices constitute the first 
category of retarding materials, also classed as plastic matrix systems. 
The second class represents hydrophobic and water-insoluble materials, which 
are potentially erodible; while the third group includes polymers those form 
hydrophilic matrices. 
Plastic matrix systems, due to their chemical inertness and drug embedding 
ability, have been widely used for controlling the release of the drug. Liquid 
penetration into the matrix is the rate-limiting step in such systems unless 
channeling agents are used. The hydrophobic and waxy materials, on the other hand, 
are potentially erodible and control the release of drug through pore diffusion and 
erosion. Polymers belonging to hydrophilic matrix systems, when exposed to an 
aqueous medium, does not disintegrate, but immediately after hydration develops a 
highly viscous gelatinous surface barrier, which controls the drug release from, and 
the liquid penetration into the center of the matrix system. 
The use of hydrophilic polymers is actually the most used method in 
controlling the release of drugs in the formulation of oral pharmaceutical dosage 
forms. Hydroxy propyl methylcellulose has been extensively used since the early 
1960s as a rate controlling polymer in oral extended-release dosage forms
14
. 
Hydrophilic matrix systems are popular and versatile controlled release 
system. Amongst polysaccharide derivatives used to produce such systems, these are 
a range of cellulose ethers, e.g. hydroxyl propyl methylcellulose (HPMC) and a 
diverse range of other materials, including sodium alginate, carrageenan, chitosan, 
and xanthan gum. 
 
1.2.3 Materials used as Retardants in matrix tablets 
Various polymers have been investigated as drug retarding agents, each presenting a 
different approach to the matrix system. Based on the features of retarding polymer, 
matrix systems are usually classified into three main groups. They are: 
Insoluble, Inert   
 Polyethylene  
 Polyvinylchloride  
 Ethyl cellulose 
  Methyl acrylate  
Insoluble, Erodible 
 Carnauba wax  
 Stearyl alcohol  
 Stearic acid 
 Polyethylene glycol  
 Castor wax  
 Triglycerides 
 Hydrophilic  
 Methyl cellulose  
 Hydroxy ethyl cellulose  
 Hydroxy propyl methyl cellulose  
 Carboxy methylcellulose sodium  
 Carboxy polyethylene 
 Xanthan gum 
 Sodium alginate 
 Chitosan 
 
1.2.5 Methods of preparation:
 36 
Three methods may be used to disperse drug and additives in a retardant 
base. 
1.2.5.1   Solvent evaporation technique   
In this technique a solution or dispersion of a drug and additive is 
incorporated into molten wax phase and the solvent is removed by evaporation. 
1.2.5.2   Compression technique 
 This involves the compression of granules, which may be prepared by wet 
granulation or dry granulation technique or direct compression of blend of drug, 
release retardant material and other additives. Drug, Polymer and the 
microcrystalline cellulose are passed through suitable sieveno.20. The powders are 
made into a wet mass by using 1:1 ratio of methanol: water. The wet mass was 
passed through a suitable sieveno.16 and the granules are dried by keep it in hot-air 
oven and the dried granules are passed through sieveno.21 and lubricated with talc 
and magnesium stearate. The lubricated granules were compressed by using rotary 
tablet punching machine.  
1.2.5.3   Fusion technique 
Drug and additives are blended into the molten wax matrix at a temperature 
slightly above melting point more uniform dispersion can be obtained by this 
technique. 
1.2.6.2. Process variables: 
1.2.6.2.1. Compression force: 
 For HPMC tablets, although the compression force had a significant effect 
on tablet hardness, its effect on drug release from HPMC tablets was minimal. It 
could be assumed that the variation in compression force should be closely related to 
a change in the porosity of the tablets. However, as the porosity of the hydrated 
matrix is independent of the initial porosity, the compression force seems to have 
little influence on drug release.Changes in compression force or crushing strength 
had minimal effect on drug release from HPMC matrix tablets once critical hardness 
was reached. Increased dissolution rates were observed when the tablets were found 
to be extremely soft, and this phenomenon was attributed to a lack of powder 
compaction, as tablet hardness was only 3 kp. 
1.2.6.2.2 Tablet shape: 
The size and shape of the tablet for the matrix system undergoing diffusion and 
erosion might impact the drug dissolution rate. Modification of the surface area for 
metoprolol tartrate tablets formulated with Methocel® K100LV from the standard 
concave shape (0.568 sq. in.) to caplet shape (0.747 sq. in.) showed an 
approximately 20-30% increase in dissolution at each time point. 
1.2.6.2.3 Tablet size: 
For tablets having the same aspect ratio and drug concentration, tablet size had a 
very strong influence on the release rate; within 24 hours, 99.8% was released from 
the small tablets, 83.1% from the medium size and 50.9% from the large tablets. It 
was hypothesized that the smaller tablets released drug more rapidly due to an 
increased surface area per volume. Additionally, it was concluded that larger 
diffusion pathways existed in the larger tablet leading to a decrease in drug release. 
1.2.6 Mechanism of drug release from matrix tablets: 
Figure 5 shows the schematic drug release from matrix diffusion controlled-
release drug delivery systems in which the drug homogenously dispersed 
in  hydrophilic matrices, formation of the gel layer and its dynamics as a function of 
time determines the drug release. Gel layer thickness, which determines the 
diffusion path length of the drug, corresponds to the distance between the diffusion 
and erosion fronts. As the swelling process proceeds, the gel layer gradually 
becomes thicker, resulting in progressively slower drug-release rates; however, due 
to continuous hydration, polymer disentanglement occurs from the surface of the 
matrix, resulting in a gradually decreasing depletion zone and an increased 
dissolution rate.  
 
 Fig .5: Drug release from matrix tablets 
1.3 KINETICS OF DRUG RELEASE:
 
The release of drug from controlled devices is via dissolution of the matrix or 
diffusion of drug through the matrix or a combination of the two mechanisms. 
1.3.1 Dissolution controlled systems 
A drug with slow dissolution rate will demonstrate sustaining properties, since 
the release of the drug will be limited by the rate of dissolution. In principle, it 
would seem possible to prepare extended release products by decreasing the 
dissolution rate of drugs that are highly water-soluble. This can be done by: 
 preparing an appropriate salt or derivative 
 coating the drug with a slowly dissolving material – encapsulation 
dissolution control 
 incorporating the drug into a tablet with a slowly dissolving carrier – matrix 
dissolution control (a major disadvantage is that the drug release rate 
continuously decreases with time) 
 The dissolution process can be considered diffusion-layer-controlled, where 
the rate of diffusion from the solid surface to the bulk solution through an unstirred 
liquid film is the rate-determining step. The dissolution process at steady-state is 
described by the Noyes-Whitney equation: 
dc/dt=Kd.A. (Cs-C)=D/h.A. (Cs-C)       Eq:1. 
Where:- 
 dc/dt - dissolution rate 
 kd - the dissolution rate constant (equivalent to the diffusion coefficient 
divided by   the thickness of the diffusion layer D/h) 
 D - Diffusion coefficient 
 Cs - saturation solubility of the solid 
 C - Concentration of solute in the bulk solution 
Equation 1,Predicts that the rate of release can be constant only if the following 
parameters are held constant: surfacearea, diffusion coefficient, and diffusion layer 
thickness and concentration difference. 
However, under normal conditions, it is unlikely that these parameters will remain 
constant, especially surface area, and this is the case for combination diffusion and 
dissolution systems.
 
1.3.2 Diffusion controlled systems: 
Diffusion systems are characterized by the release rate of a drug being 
dependent on its diffusion through an inert membrane barrier, which is usually a 
water-insoluble polymer. 
In general, two types or subclasses of diffusion systems are recognized: 
reservoir devices and matrix devices
41
 
1.3.2.1. Reservoir devices: 
 ER formulations, where film coating constitutes the main factor in 
controlling drug release. Examples of materials used to control drug release include 
hardened gelatin, methyl or ethyl cellulose, polyhydroxymethacrylate, methacrylate 
ester copolymers, and various waxes. Ethyl cellulose and methacrylate ester 
copolymers are the most commonly used systems in the pharmaceutical industry. 
 
1.3.2.2. Matrix extended release systems 
In this model, drug in the outside layer exposed to the bathing solution is 
dissolved first and then diffuses out of the matrix. This process continues with the 
interface between the bathing solution and the solid drug moving toward the interior. 
It follows that for this system to be diffusion controlled, the rate of dissolution of 
drug particles within the matrix must be much faster than the diffusion rate of 
dissolved drug leaving the matrix 
41
. 
Derivation of the mathematical model to describe this system involves the following 
assumptions: 
 a)    A pseudo-steady state is maintained during drug release; 
 b)    The diameter of the drug particles is less than the average distance of 
drug   diffusion through the matrix; 
 c)    The diffusion coefficient of drug in the matrix remains constant (no 
change   occurs in the characteristics of the polymer matrix
41
 . 
 d)    The bathing solution provides sink conditions at all times; 
 e)    No interaction occurs between the drug and the matrix; 
 f)    The total amount of drug present per unit volume in the matrix is 
substantially   greater than the saturation solubility of the drug per unit 
volume in the matrix   (excess solute is present) 
 g)    Only the diffusion process occurs 
44
 . 
 
 
 Fig. 6 : Schematic representation of a matrix release system 
Release from a monolithic matrix system can be graphically depicted as in shown in 
Figure 1  
The release behaviour for the system can be mathematically described by the 
following equation: 
       
 Eq :2 
Where, 
 dM - change in the amount of drug released per unit area 
 dh - change in the thickness of the zone of matrix that has been depleted 
  of drug 
 Co - total amount of drug in a unit volume of matrix 
 Cs - saturated concentration of the drug within the matrix. 
Additionally, according to diffusion theory: 
   
 Eq: 3  
Where, 
 Dm - is the diffusion coefficient in the matrix. 
 h - Thickness of the drug-depleted matrix 
 dt - change in time 
By combining equation 2 and equation 3 and integrating: 
  
M = [Cs.Dm.(2Co-Cs).t]
1/2     
 Eq :4 
When the amount of drug is in excess of the saturation concentration, then: 
  
M = [2.Cs.Dm.Co.t]
1/2     
 Eq :5 
Equation 4 and equation 5 relate the amount of drug release to the square-root of 
time. Therefore, if a system is predominantly diffusion controlled, then it is expected 
that a plot of the drug release vs. square root of time will result in a straight line. 
Drug release from a porous monolithic matrix involves the simultaneous penetration 
of surrounding liquid, dissolution of drug and leaching out of the drug through 
tortuous interstitial channels and pores. The volume and length of the openings must 
be accounted for in the drug release from a porous or granular matrix: 
  
M = [Ds.Ca.p/T.(2Co-p.Ca).t]
1/2    
 Eq :6 
Where: 
 p - Porosity of the matrix 
 t - Tortuosity 
 Ca - solubility of the drug in the release medium 
 Ds - Diffusion coefficient in the release medium. 
 T – Diffusional pathlength 
For pseudo steady state, the equation can be written as: 
  
M = [2D.Ca.Co.p/T.t]
1/2     
 Eq :7 
The total porosity of the matrix can be calculated with the following equation: 
  P=Pa+Co/ρ+Cex/ρex      
 Eq:8 
 
Where: 
 P – Porosity 
 ρ – Drug density 
 Pa – porosity due to air pockets in the matrix 
 ρex – density of the water soluble excipients 
 Cex – concentration of water soluble excipients 
For the purpose of data treatment, equation 6 can be reduced to: 
  M = k.t 1/2      
 Eq :9 
       Where, k is a constant, so that the amount of drug released versus the square 
root of time will be linear, if the release of drug from matrix is diffusion-controlled. 
    If this is the case, the release of drug from a homogeneous matrix system can be 
controlled by varying the following parameters: 
•     Initial concentration of drug in the matrix 
•     Porosity 
•     Tortuosity 
•     Polymer system forming the matrix 
•     Solubility of the drug . 
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2.1 EXTENDED RELEASE MATRIX SYSTEMS: 
           Mohammad MahiuddinTalukdar et.al 
38 
conducted a study on xanthan 
gum and hydroxylpropylmethylcellulose as matrices for controlled release drug 
delivery1. Composition and in vitro drug release behaviour. In respect of controlled 
drug release behaviour xanthan gum matrices have some important pharmaceutical 
as well as economic advantages (e.g., absence of initial burst release, higher drug-
retarding ability, and more reproducibility in drug release, and the possibility of 
zero-order release kinetics) over HPMC matrices. Considering the influence of ionic 
strength of the medium on drug release behaviour xanthan gum has a disadvantage 
that the drug release is influenced by the total salt concentration within the range of 
gastro-intestinal tract, while the drug release from HPMC matrices is independent of 
ionic strength. But this ionic strength dependency should not be considered as a total 
failure of XG for controlling the drug release. Compaction characteristics between 
the two polymers are quite similar, but the flow ability of xanthan gum is better than 
that of HPMC. 
 
         Johan Hjartstamet.al
39  
studied the effect of hydroxyl group content in ethyl 
cellulose on permeability in free films and coated membranes the change in the 
water permeability, glass transition temperature, and mechanics properties of ethyl 
cellulose with different degrees of substitution are presented. Studies of the hydroxyl 
group content on the polymer chain indicate that the mechanical properties of a free 
film decrease as the hydroxyl group content decreases. This is thought to be due to 
the lower solubility of ethyl cellulose with a lower degree of substitution, as 
determined by the interaction constant in ethanol and the ability of the film with a 
high hydroxyl group content to hold more water. Furthermore,  an increase in 
hydroxyl group content, the higher the drug release rate and, at the same time, the 
decrease in Vickers hardness. 
 
 Wikstrand John et.al
40 
conducted a study about  pharmacokinetic 
considerations of formulation, extended release metoprolol Succinate in the 
treatment of Heart failure. Extended release metoprolol succinate is a controlled 
release formulation designed to deliver metoprolol succinate at a near constant rate 
for approximately 20hr, independent of food intake and gastrointestinal pH. Once 
daily dosing of ER metoprolol succinate 12.5-200mg produces even plasma 
concentrations over a 24h period, without the marketed peaks and troughs 
characteristically observed with the immediately release formulation. This leads to 
consistent beta -1-blockade over 24h, while maintaining cardio selectivity at a dose 
upto 200Mg daily, Pharmacokinetics studies have also been performed in heart 
failure patients and have demonstrated that ER metoprolol succinate is associated 
with a more pronounced and even beta-1-blockade over a 24h period than IR 
formulation, The efficiency and good tolerability of ER metoprolol succinate in 
heart failure patients has now been demonstrated in a large-scale trial. 
 Mamoru Fukuda et al
41 
studied the properties of sustained release hot-melt 
extrudedtablets containing chitosan and xanthan gum. The aim of this study was to 
investigate the influence of pH, buffer species and ionic strength on the release 
mechanism of chlorpheniramine maleate (CPM) from matrix tablets containing 
chitosan and xanthan gum prepared by a hot-melt extrusion process. Drug release 
from hot-melt extruded (HME) tablets containing either chitosan or xanthan gum 
was pH and buffer species dependent and the release mechanisms were controlled 
by the solubility and ionic properties of the polymers. All directly compressed (DC) 
tablets prepared in this study also exhibited pH and buffer species dependent release. 
In contrast, the HME tablets containing both chitosan and xanthan gum exhibited pH 
and buffer species independent sustained release. When placed in 0.1N HCl, the 
HME tablets formed a hydrogel that functioned to retard drug release in subsequent 
pH 6.8 and 7.4 phosphate buffers even when media contained high ionic strength, 
whereas tablets without chitosan did not form a hydrogel to retard drug release in 
0.1N HCl. The HME tablets containing both chitosan and xanthan gum showed no 
significantchange in drug release rate when stored at 40 ◦C for 1 month, 40 ◦C and 
75% relative humidity (40 ◦C/75% RH) for 1 month, and 60 ◦C for 15 days. 
VinessPillay and Reza Fassihi et.al
42
developed a novel monolithic drug 
delivery system for highly water-soluble bioactive agents to follow pH-
independent zero-order kinetics is described. The system utilizes a hydrophilic gel-
based swellable polymeric material (polyethylene oxide), a model drug (metoprolol 
tartrate, 100% water soluble at 25°C) and different electrolytes, such as sodium 
carbonate and/or pentasodiumtripolyphosphate. Based on the induction of in situ 
intra-gel chemical reactions between different ionic species, drug and polymer, a 
heterogeneous structure manifested as „peripheral boundary stiffening,‟ is 
accomplished. The consequence of these interactions essentially include the 
development of gradient-controlled matrix swelling as elucidated through textural 
profiling, which may contribute to inhibition of drug solubility and its outward 
diffusion. Analysis of textural profiles and photo microscopy distinctly provides 
information on the disposition of peripheral boundary densification for the 
electrolyte-containing matrices. Electrolytic conductivity measurements performed 
with the simultaneous analysis of matrix swelling showed that sodium carbonate 
forms a highly reactive matrix within the first 3 h of medium penetration. On the 
other hand, larger molecules such as pentasodiumtripolyphosphate maintain a 
constant conductivity level, which may be related to its lower solubility and 
diffusion in comparison to sodium carbonate. Based on model fitting and statistical 
analysis, it is shown that drug release kinetics were adequately described by 
Mt/M∞=k0t, with zero-order release rate constant k0 of 0.054 h
−1
. This novel 
approach in formulation development could potentially be used for constant rate 
delivery of highly soluble bioactive agents over an extended period for specific 
biopharmaceutical needs. 
Thomas Durig et al 
43 
studied the effect of guar-based monolithic matrix 
systems: effect of ionizable and non-ionizable substances and excipients on gel 
dynamics and the release kinetics  Tablet dissolution, erosion and water uptake 
studies were carried out using a modified USP 23 Apparatus 2 method. The kinetics 
of gel strength and texture development were studied by textural analysis. Near 
linear drug release over 24 h was obtained from formulations containing water 
soluble, ionizable sodium chloride and glycine. The contribution of Fickian release 
to overall drug release was lowest for these formulations and was correlated with 
greater gel strength and lower water uptake in the early time period. For soluble 
sugars (lactose and sucrose) the Fickian contribution to overall drug release was 
large and associated with pronounced curvilinear profiles. Water uptake was greatest 
for these additives (450% in 6 h). The lowest water uptake and negligible matrix 
erosion was observed for microcrystalline cellulose. Release from this formulation 
was predominantly Fickian. It was found that the physicochemical nature of added 
excipients significantly influences the release kinetics from guar-based formulations. 
Ionic, water soluble materials (sodium chloride, glycine) reduce initial hydration of 
the matrix and thus have the ability to limit the initial rapid diffusion of drug and to 
sustain near linear release over 24 h. 
Howard et.al
44
studied the  controlled release formulation is provided which 
release a pharmaceutical of a basic character at a controlled rate regardless of the pH 
of the environment, Which formulation includes a basic pharmaceutical upto about 
45% by weight of a pH dependent polymer which is a salt of alginic acid, such as 
sodium alginate, upto about 35% weight of a pH independent hydrocarbon gelling 
agent having a viscosity of upto about 100,000 centiposes in 2% solution at 20
0 C
., 
binder and excipient‟s. 
. 
Salsa et.al
45 
reported the oral controlled- release dosage forms.1. Cellulose 
ether polymers in hydrophilic matrices. An appropriate designed controlled-release 
drug delivery system can be a major advance towards solving problems concerning 
the targeting of a drug to a specific organ or tissue and controller the rate of drug 
delivery to the target tissue.Hydrophillic matrices are an interesting option when 
developing an oral controlled-release formulation. The present study focuses on oral 
controlled-release dosage forms and the application of cellulose ether polymers in 
hydrophilic matrices. 
 Appelgren et.al
47
studied the pharmaceutical composition comprising of 
metoprolol succinate. The present invention related to metoprolol succinate, a new 
therapeutically active compound and pharmaceutical preparations comprising this 
new compound. 
 
  
 
AIM, OBJECTIVE  
& 
PLAN OF WORK 
 
 
 
 
 
 
3.AIM 
The aim of the present study relates to the development of extended release 
matrix tablets containing metoprolol succinate for the treatment of antihypertensive.  
4.OBJECTIVES AND PLAN OF WORK 
Controlled release drug delivery systems are designed by different 
techniques like enteric coating, osmotic pump, pro drugs, transdermal patches and 
matrix tablets. Among the various techniques used, recently the attention of 
pharmaceutical researchers has been attracted by the matrix tablets because of their 
ease of manufacturing. Different types of polymers are used to control the release of 
drugs from the dosage forms for absorption by the human body. Though a variety of 
polymeric substances are available to serve as release retarding matrix materials 
there is a continued need to develop new, safe and effective release retarding 
materials for matrix tablets. Natural gums and polysaccharides and their derivatives 
represent a group of polymers widely used in pharmaceutical dosage forms due to 
their non-toxicity, low cost and free availability. Natural gums and hydrophilic 
polymers and where in contact with water, they are hydrated to form a gel. Because 
of this property natural gums like gum karaya, xanthan gum and olibanun gum have 
been reported as good matrix materials for sustained release dosage forms. 
 Xanthan gum is compatible with variety of active ingredients and other 
excipients and readily hydrates, absorb water and swell quickly. Because of their 
hydrophilic nature and highly cross-linked structure they are more suitable material 
for use in controlled release drug delivery systems. 
Metoprolol succinate is an Antihypertensive drug under β1 adrenergic 
receptor antagonist. Being a class 1 molecule under BCS classification it eliminates 
faster from the body (conventional dosage form).It‟s short biological half life (3-
7hrs) that calls for frequently daily dosing (2 to3 times) and therapeutic use in 
chronic anti-hypertensive disease necessitates its formulation into extended release 
dosage form.  So it is formulated as extended release matrix formulation. 
The objective of the present study was to formulate metoprolol succinate 
extended release matrix tablets using xanthan gum (natural polymer) and to 
elucidate the release kinetics of metoprolol succinate from xanthan gum-matrices. 
Here, an attempt was made to develop extended release metoprolol succinate matrix 
tablets 
Hence, the objectives of the present work include: 
 To prepare a stable and robust formulation containing metoprolol succinate and 
to compare with the innovator product Toprol XL. 
 To prepare a pharmaceutical equivalent formulation of metoprolol succinate 
matrix formulation. 
 To prepare a stable and robust formulation of metoprolol succinate matrix tablet 
meeting USP specifications. 
 To prepare a stable and robust formulation of extended release matrix 
formulation for BCS class1 molecule, metoprolol succinate. 
 
 
 
 
 
 
 
 
 
 
 4.1 Plan of work:     
PREFORMULATION STUDIES 
 Physical parameters: Bulk density 
   Tapped density 
   Compressibility index 
   Angle of repose 
   Hausner‟s ratio 
 Drug –excipient compatibility studies 
 ESTIMATION OF DRUG  
 FORMULATION DEVELOPMENT 
 EVALUATION OF FORMULATION 
 Physical parameters:  Hardness,  
 Friability, 
 Weight variation  
 Drug content 
 Dissolution 
 
 Stability Studies 
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 5.1.DRUG PROFILE: 
 Physico-chemical properties: 
Drug                     : Metoprolol succinate 
  Description : white powder, free from the visible extraneous matter. 
             Chemical Name           :    2-propanol, 1-(4-(2-methoxyethyl)phenoxy)  
 -3-((1-methylethyl) amino)-, (±) butaedioate(2:1)(salt) 
  Molecular Formula  :(C15H25 NO3)2C4H6O4 
      Structure:                                                OH 
                                                      OCH2CHCH2NHCH (CH3)2         
                                                                                                                          
COOH   
                                                                                                           CH2 
                                                                  CH2CH2OCH3                                
.CH2                    
                                                                                                           COOH 
 
 
Molecular weight  :  652.81 
Melting point   : 120ºc   
 Solubility   : Freely Soluble in water, Soluble in 
methanol, 
  Sparingly soluble in alcohol & 
  Practically insoluble in 
dichloromethane 
BCS Class   : Class 1 
 
 
 
 PharmacoKinetics/Dynamics: 
 Tmax    :1.5-2 hrs oral regular; 6-12 hrs 
(longacting) 
   Bioavailability  :50% 
  Plasma protein binding :12% 
  Route of metabolism  :Hepatic by oxidative deamination  
  Route of excretion  :Renal 
  Halflife   :3-7hrs 
  P
ka    
:9.68 
 Mechanism of action: 
Metoprolol is a β1 selective adrenergic receptor blocking agent. The 
precise mechanism of anti-hypertensive effect is not known. Possible 
mechanisms include reduced cardiac output, decreased sympathetic out flow 
to peripheral vasculature, and inhibition of renin release by the kidneys. 
 Therapeutic Uses:     Antianginal and          
   Antihypertensive 
 Dosage: 
Tablet, Extended release, as Succinate: 25mg, 50mg, 100mg, 200mg 
[expressed as mg equivalent to tartarate] 
 Over Dose: 
Cardiac disturbances, CNS toxicity, Bronchospasm, Hypoglycemia, and 
Hyperkalemia 
 Storage: 
Tablet:Store between 15
0
C to 30
0
C 
 
 
5.2. EXCEPIENTS PROFILE: 
5.2.1.Xanthan gum
 
    General Description: 
              i. Name    : NonproprietaryBP: Xanthan gum, USPNF: 
Xanthangum 
ii. Synonyms              :  Corn Sugar Gum; E415; Keltrol; 
polysaccharide       B-1459; 
Rhodigel;  Vanzan NF;       Xantural. 
iii. Chemical Name  :         Xanthan gum  
iv. Empirical Formula :          (C35H49O29) n 
v. Molecular Weight  :            Approximately 2 × 10
6
 
vi. Functional Category : Stabilizing agent, suspending agent, 
viscosity-      increasing agent.
 
   Description: 
Xanthan gum occurs as a cream or white colored, odorless, free-flowing, fine 
powder. 
    Properties 
Acidity/alkalinity  : pH = 6.0–8.0 for a 1% w/v aqueous 
Solution. 
Freezing point  :   0°C for a 1% w/v aqueous solution. 
Heat of combustion  :   14.6 J/g (3.5 cal/g) 
Melting point   :    270°C. 
Particle size distribution :  Various grades with different particle sizes 
are available; for example, 100% less than 180 μm in size for Keltrol CG; 100% less 
than 75 μm in size for Keltrol CGF; 100% less than 250 μm, 95% less than 177 μm 
in size for Rhodigel; 100% less than 177 μm, 92% less than 74 μm in size for 
Rhodigel 200. 
Refractive index :   n
20
D = 1.333 for a 1% w/v aqueous solution. 
    Solubility                   :       PracticallSy insoluble in ethanol and ether;  
 Soluble in cold or warm water. 
Specific gravity :   1.600 at 25°C 
Viscosity (dynamic) :   1200–1600 mPa s (1200–1600 cP) for a 1% 
w/v      
Aqueous solution at 25°C. 
Stability 
 
Xanthan gum is a stable material. Aqueous solutions are stable over a wide 
pH range (pH 3–12), although they demonstrate maximum stability at (pH 4–10) 
and temperatures of 10–60°C. Xanthan gum solutions of less than 1% w/v 
concentration may be adversely affected by higher than ambient temperatures: for 
example, viscosity is reduced. Solutions are also stable in the presence of enzymes, 
salts, acids, and bases.      
Storage Conditions 
The bulk material should be stored in a well-closed container in a cool, dry 
place. 
Incompatibilities 
 
Xanthan gum is incompatible with oxidizing agents, some tablet film-
coatings, carboxymethylcellulose sodium, dried aluminum hydroxide gel and some 
active ingredients such as amitriptyline, tamoxifen and verapamil. 
Safety  
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics and food products and is generally regarded as nontoxic and nonirritant at 
the levels employed as a pharmaceutical excipient.The estimated acceptable daily 
intake for xanthan gum has been set by the WHO at up to 10 mg/kg body-weight.  
 
Related Substances 
Ceratonia; guar gum 
Applications in Pharmaceutical Formulation or Technology 
 
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics and foods as a suspending and stabilizing agent. It is also used as a 
thickening and emulsifying agent. It is nontoxic, compatible with most other 
pharmaceutical ingredients and has good stability and viscosity properties over a 
wide pH and temperature range. Xanthan gum gels show pseudo plastic behavior, 
the shear thinning being directly proportional to the shear rate. The viscosity returns 
to normal immediately on release of shear stress 
Although primarily used as a suspending agent, xanthan gum has also been 
used to prepare sustained-release matrix tablets. Xanthan gum has been incorporated 
in an ophthalmic liquid dosage form, which interacts with mucin, thereby helping in 
the prolonged retention of the dosage form in the pre-corneal area  
Recent studies have revealed that xanthan gum can also be used as an 
excipient for spray-drying and freeze-drying processes for better results.  
Xanthan gum can be used to increase the bio adhesive strength in vaginal 
formulations and as a binder in colon specific drug delivery systems. Xanthan gum 
is also used as a hydrocolloid in the food industry and in cosmetics it has been used 
as a thickening agent in shampoo.  
5.2.2. Microcrystalline Cellulose 
Physico chemical properties 
Description 
 Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odourless, tasteless, crystalline powder composed of porous 
particles. It is commercially available in different particle size Stretching and 
moisture grades that have different properties and applications. 
Formula                  :   (C 6H10 O5) 
Molecular weight  :    n~220 
Density (bulk)       :    0.32 g/cm
3  
 
Density (tapped)   :    0.45g/cm
3
 
Density (true)       :     1.512-1.668 g/cm
3
 
Melting point       :     Chars at 260-270 
0
 C. 
Solubility              :     Slightly soluble in 5% W/V sodium hydroxide solution; 
                                    Practically insoluble in water, dilute acids, and most organic 
solvents. 
Application in pharmaceutical Formulation Technology  
   Microcrystalline cellulose is widely used in pharmaceuticals primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet 
granulation and direct-compression process. In addition to its use as a binder 
/diluent, microcrystalline cellulose also has some lubricant and disintegrant 
properties that make it useful in tableting.  
Functional Category  
  Adsorbent; suspending agent,  tablet and capsule diluent, tablet disintegrant. 
Use of Microcrystalline cellulose  
  
 
 
 
 
 
 
Use Concentration (%) 
Adsorbent 20-90 
Anti-adherent 5-20 
Capsule binder/ diluent 20-90 
Tablet disintegrant 5-15 
Tablet binder/ diluent 20-90 
Incompatibilities 
 Microcrystalline cellulose is compatible with strong oxidizing agents 
Method of Manufacture 
   Microcrystalline cellulose is manufactured by the controlled hydrolysis with 
dilute mineral acid solutions of a-cellulose obtained as a pulp from fibrous plant 
materials. Following hydrolysis, the hydrocellulose is purified by filtration and the 
aqueous slurry is spray-dried to form dry, porous particles of a broad-size 
distribution 
Safety 
 Microcrystalline cellulose is widely used in oral pharmaceutical 
formulations and food products and is generally regarded as a nontoxic and non-
irritant material. Microcrystalline cellulose is not absorbed systemically following 
oral administration and thus has little toxic potential. Consumption of large 
quantities of cellulose may, however, have a laxative effect, although this is unlikely 
to be a problem when cellulose is used as an excipient in pharmaceutical 
formulations 
5.2.3.Hydroxypropylmethylcellulose (HPMC) 
Nonproprietary names: 
BP:HypromelloseJP: Hydroxypropylmethylcellulose,PhEur: Hypromellosum,USP: 
Hypromellose. 
 Synonyms: 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; 
Tylopur. 
 Chemical name:     Cellulose hydroxypropyl methyl ether. 
 Functional category: 
Coating agent; film-former; rate-controlling polymer for sustained release; 
stabilizing agent; suspending agent; tablet binder; viscosity-increasing agent. 
 Description: 
Hypromellose is an odourless and tasteless, white or creamy-white fibrous or 
granular powder. 
 Solubility: 
Soluble in cold water, forming a viscous colloidal solution;  practically 
insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol 
and dichloromethane, mixtures of methanol and dichloromethane, and mixtures of 
water and alcohol. Certain grades of  hypromellose are soluble in aqueous acetone 
solutions, mixtures of dichloromethane and propan-2-ol, and other organic solvents. 
 Viscosity: 
A wide range of viscosity types are commercially available. Aqueous 
solutions are most commonly prepared, although hypromellose may also be 
dissolved in aqueous alcohols such as ethanol and propan-2-ol provided the alcohol 
content is less than 50% w/w. Dichloromethane and ethanol mixtures may also be 
used to prepare viscous hypromellose solutions. Solutions prepared using organic 
solvents tend to be more viscous; increasing concentration also produces more 
viscous solutions. 
 Stability and storage conditions: 
Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3–11. Increasing temperature reduces the viscosity 
of solutions. Hypromellose undergoes a reversible sol–gel transformation upon 
heating and cooling, respectively. The gel point is 50–90°C, depending upon the 
grade and concentration of material. Aqueous solutions are comparatively enzyme-
resistant, providing good viscosity stability during long-term storage. However, 
aqueous solutions are liable to microbial spoilage and should be preserved with an 
antimicrobial preservative, when hypromellose is used as a viscosity-increasing 
agent in ophthalmic solutions; benzalkonium chloride is commonly used as the 
preservative. Aqueous solutions may also be sterilized by autoclaving; the 
coagulated polymer must be re-dispersed on cooling by shaking. 
Hypromellose powder should be stored in a well-closed container, in a cool 
and dry place. 
 Applications: 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. 
In oral products, hypromellose is primarily used as a tablet binder, in film-
coating and as a matrix for use in extended-release tablet 
formulations.Concentrations between 2% and 5% w/w may be used as a binder in 
either wet- or dry-granulation processes. High-viscosity grades may be used to 
retard the release of drugs from a matrix at levels of 10–80% w/w in tablets and 
capsules. 
Depending upon the viscosity grade, concentrations of 2–20% w/w are used 
for film-forming solutions to film-coat tablets. Lower-viscosity grades are used in 
aqueous film-coating solutions, while higher-viscosity grades are used with organic 
solvents. Hypromellose is also used as a suspending and thickening agent in topical 
formulations. Compared with methylcellulose, hypromellose produces aqueous 
solutions of greater clarity, with fewer undispersed fibers present, and is therefore 
preferred in formulations for ophthalmic use. Hypromellose at concentrations 
between 0.45–1.0% w/w may be added as a thickening agent to vehicles for eye 
drops and artificial tear solutions. 
Hypromellose is also used as an emulsifier, suspending agent, and stabilizing 
agent in topical gels and ointments. As a protective colloid, it can prevent droplets 
and particles from coalescing or agglomerating, thus inhibiting the formation of 
sediments. 
In addition, hypromellose is used in the manufacture of capsules, as an 
adhesive in plastic bandages, and as a wetting agent for hard contact lenses. It is also 
widely used in cosmetics and food products. 
Sizes and moisture grades  that have different properties and applications. 
5.2.4.Magnesium Stearate 
Description: 
Magnesium stearate is a fine, white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic 
taste. The powder is greasy to touch and readily adheres to the skin. 
Molecular weight     :      591.34 
Structural Formula   :       [CH3 (CH2) 16 COO] 2 Mg   
Crystalline Forms: 
High purity magnesium stearate has been isolated as a trihydrate, adihydrate 
and an anhydrate 
Flow ability  : Poorly flowing, cohesive powder 
Meltingrange  : 117-150
o
C (commercial samples) 126-130
o
C (high 
purity      magnesiumstearate) 
Solubility: 
 Practically insoluble in ethanol, ethanol (95 %), ether and water; slightly 
soluble   in warm benzene and warm ethanol (95 %) 
 Specific surface area  : 1.6-14.8 m 
2
 /g 
 Functional category  : Tablet and capsule lubricant  
Applications in Pharmaceutical Formulation Technology: 
It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25 % and 5.0 % w/w. 
Incompatibilities: 
Incompatible with strong acids, alkalis and iron salts.Strong oxidizing 
materials. Magnesium stearate cannot be used in products containing aspirin, some 
vitamins and most alkaloid salts 
 
 
 
Method of Manufacture: 
Magnesium stearate is prepared either by the interaction of aqueous solutions 
of magnesium chloride with sodium stearate or by the interaction of magnesium 
oxide, hydroxide or carbonate with stearic acid at elevated temperatures. 
Safety: 
Magnesium stearate is widely used as a pharmaceutical excipient and is 
generally regarded as being nontoxic following oral administration. However, oral 
consumption of large quantities may result in some laxative effect or mucosal 
irritation. 
 
 
 
 
  
 
 
 
 
 
 
METHODOLOGY 
 
 
 
 
 
 
 
 
 
6.1. MATERIALS: 
Table 2. List of materials used 
S.NO MATERIAL SOURCE 
1. Metoprolol succinate Dr.Reddylabs 
2. Xanthan gum M/S Jungbuzlauer, Austria 
.3. MCC FMC  
4. HPMC5cps Colorcon 
5. HPMC100cps Colorcon 
6. Magnesium stearate Ferro 
7. Lactose DMV 
8. Potassium di hydrogen phosphate Merck  
9. Sodium hydroxide Merck  
10. Potassium di hydrogen phosphate 
monohydrate 
Merck  
11. Ortho phosphoric acid Qualigens 
12. Acetonitrile S.D fine chemicals 
13. Ethanol Hong yang 
14. HCL Merck 
 S.NO EQUIPMENTS SOURCE 
1. Digital balance Sagtoriouse 
2. Electronic balance Metler 
3. UV-Visible spectrophotometer Perkinelmar-Win lab 
4. Rapid dryer Retsct TG 200 
5. Tapped density apparatus 
(USP) 
Electro Lab 
6. Planetary mixer Kenwood 
7. RMG Sacal 
8. FBC Glatt 
9. Bleder Vamp 
10. Multi mill Ganson 
11. Shifter Gansons limited 
12. Rotary compression machine Cadmach, 16 Stations 
13. Fribilator Electro Lab 
14. Hardness tester Thermo lab 
15. Dissolution apparatus Lab India, India 
16. Digital pH meter Thermo andMetrom 
17. Vernier calipers  
18. 
 
HPLC Agilent-Empower and waters-Breeze 
19. Glass Ware Qualigens 
20 
Sieve shaker Retsch 
TABLE 3.: List Of Equipments 
 
22 Sonicator Bandelinsonorex 
23. Centrifuge Her mle 
24. Sieve Shaker Lab companion 
25 Vaccum oven Mack 
26 Water bath Thera ml 
27 KF titrator Metromin 
28 Stirrer Remi motors 
29 LOD Machine Mettler Toledo 
 
6.2.PREFORMULATION STUDIES: 
6.21.Drug – Excipient compatibility studies: 
The excipients weighed according to mentioned ratio and sifted through 
BSS # 36 and blended together. The mixture placed in two vials. One set of vials are 
stored at 4
0
C as control. The set was stored at 40
0
C/75% RH. The caps of the vials 
which were kept at 40
0
C/75% RH were punctured for the permeation of moisture. 
The vials observed after every week and compared with vials kept at 4
0
C as control 
for any physical incompatibility like lump formation, colour change. Results are 
shown in below table. 
6.2.2.Flow Properties determination: 
Certain methods are used to measure granulation and powder characteristics 
in order to monitor granulation suitability for tableting. Good flow properties are 
essential for the transport of the material through the hopper into and through the 
feed frame and in to dies.  
21 FTIR Thermo electronic corporation 
Angle of repose 
The frictional force in a loose powder can be measured by the angle of 
repose θ. It is defined as, the maximum angle possible between the surface of the 
pile of the granules and the horizontal plane. If more powder is added to the pile, it 
slides down the sides of the pile until the mutual friction of the particles producing a 
surface angle θ, is in equilibrium with the gravitational force. The angle of repose 
was determined by the funnel method suggested by Newman. The blend was poured 
through a funnel that can be raised vertically until a maximum cone height (h) was 
obtained. Radius of the heap (r) was measured and the angle of repose was 
calculated using the following formula  
           tan θ = h/r 
Therefore       θ = tan-1 ( h/r ) 
Where, 
  θ = Angle of repose  
  h = Height of the cone 
 r = Radius of the cone base 
 Table 3: Flow Properties and Corresponding Angle of Repose 
Flow Property Angle of Repose (Degrees) 
Excellent 25 – 30 
Good 31 -35 
Fair (aid not needed) 36 – 40 
Passable (may hang up) 41 – 45 
Poor (must agitate, Vibrate) 46 – 55 
Very poor 56 – 65 
Very, Very poor > 66 
Bulk Density 
  Density is defined as weight per unit volume. Bulk density Pb is defined as 
the mass of the powder divided by the bulk volume and is expressed as gm/cm
3
. The 
bulk density of a powder primarily depends on particle size distribution, particle 
shape and the tendency of particles to adhere together. There are two types of bulk 
density.  
The particles are pack in such a way so as to leave large gaps between their 
surfaces resulting up in light powder of low bulk density. Here the smaller particles 
shift between the large particles resulting in heavy powder of high bulk density. 
Bulk density is very important in the size of containers needed for handling, 
shipping and storage of raw material and blend. It is also important in size blending 
equipment 
  Apparent bulk density (Pb) was determined by pouring blend into a 
graduated cylinder. The bulk volume (Vb) and weight of the powder (M) was 
determined. The bulk density was calculated by using the following formula 
        Pb   =   M/ Vb 
Where,                 
  P b  =  Bulk Density                      
  M = Weight of sample in gm                       
  Vb = Final volume of blend in cm
3
 
Tapped Density 
 It is the ratio of total mass of the powder to the tapped volume of powder. 
The volume was measured by tapping the powder for 500 times. Then the tapping 
was done for 750 times and the tapped volume was noted. The tapped density was 
calculated by using the following formula      
            
Where,  Pt  =  M / Vt 
                         Pt  = Tapped Density 
                        M  = Weight of the sample in gm 
                        Vt  = Tapped volume of blend in cm
3  
Compressibility Index and Hausner’s ratio 
In recent years, the compressibility index and the closely related Hausner‟s 
ratio have become the simple, fast, and popular methods of predicting powder flow 
characteristics. The compressibility index has been proposed as an indirect measure 
of bulk density, size, shape, surface area, moisture content and cohesiveness of 
materials because all of these can influence the observed compressibility index. The 
compressibility index and the Hausner‟s ratio are determined by measuring both the 
bulk volume and tapped volume of a powder.  
 
Basic methods for the determination of compressibility Index and Hausner’s 
Ratio 
    While there are some variations in the method of determining the compressibility 
index and Hausner‟s ratio, the basic procedure is to measure the unsettled apparent 
volume (V0), and the final tapped volume (Vf), of the powder after tapping the 
material until no further volume changes occur. The compressibility index and the 
Hausner‟sratio are calculated as follows  
 
Alternatively, the compressibility index and Hausner ratio may be calculated using 
measured values of bulk density and tapped density as follows   
 Compressibility Index  = 100 × Tapped density / Bulk density 
  Hausner Ratio   =  Tapped density/ Bulk density 
In a variation of these methods, the rate of consolidation is sometimes 
measured rather than, or in addition to, the change in volume that occurs on tapping. 
For the compressibility index and the Hausner‟s ratio, the generally accepted scale 
of flow ability is described by Carr. The values are tabulated in the below table – 4. 
6.3API Characterization 
Determination of Bulk Density, tapped density: 
A known amount  of metoprolol succinate was taken in 50  ml measuring cylinder 
which was placed in Electro lab Tapped Density Apparatus(method USP-I). Initial 
volume (V0) of the cylinder was noted and then the cylinder was tapped 500 times 
and volume was measured. Then further an additional 750 tappings were repeated. 
No difference was noted between the volumes between two tappings (500 and 750). 
The final volume (V) was considered after completion of 750 taps. The values 
obtained are reported in the table: 3 
 
6.4. FORMULATION AND EVALUUATION OF MATRIX 
FORMULATIONS 
FORMULATIONS: 
6.4.1.Method of Selection : Extended release tablets of metoprolol succinate were 
formulated using three methods they were 
 DIRECT COMPRESSION  
 DRY GRANULATION 
 WET GRANULATION  
Formulation  X1A 
DIRECT COMPRESSION: 
Table 4 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by direct compression for X-1A. 
 Composition of the  formulation X1A 
 
 
 
Table :4 
INGREDIENTS X-1A  
                mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 24.3 
MCC(AVICEL) 229.2 
HPMC5cps 15.5 
Magnesium stearate 2.4 
Total 297 
 
 
 
 
Procedure 
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, binder, diluents, lubricant through BSS # 
40 sieve separately 
3. Blended metoprolol succinate, polymer, binder, diluents in a poly-bag 
4. Step 3 materials were blended with sifted lubricant 
5. Compressed the blend of Step 4 materials into round concave shaped tablets 
with the help of 8mm concave shaped punches 
 
Formulation X1B 
DRY GRANULATION: 
Table 5 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by dry granulation for  X-1B. 
 Composition of   the   formulation   X1B 
Table : 5 
 
 
 
 
 
Procedure: 
Weighed all ingredients accurately  
1. Sifted metoprolol succinate, polymer, binder, diluents, lubricant through BSS # 
40 sieve separately 
2. Blended metoprolol succinate, polymer, binder, diluents in a poly-bag 
3. Step 3 materials were blended with sifted lubricant 
4. That step 4 material passed through roll compact machine 
5. That step 5 material passed through #25 mesh 
6. Compressed the blend of Step 6 materials into round concave shaped tablets 
with the help of 8mm concave shaped punches 
 
 
INGREDIENTS X-1B 
mg/tab 
Metoprolol succinate 25.5 
Xanthan gum 28.8 
MCC (AVICEL 102) 228 
HPMC5cps 13.2 
Magnesium stearate 2.4 
Total 297.9 
Formulation X1C 
WET GRANULATION:  
Table 6 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by wet granulation by X 1C. 
Composition of the formulation   X1C 
Table :6 
 
 
 
 
 
 
 
 
 
 
 
 
Procedure: 
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in planetary mixer 
4. Prepared HPMC 5cps binder solution (Take 95 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition above binder solution 
7. Wet granules of Step 6 were dried at 60oC for 45 minutes. (Up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
INGREDIENTS 
X-1C 
mg/tab 
Metoprolol succinate 25.7 
Xanthan gum 30.2 
MCC (AVICEL 102) 224.6 
HPMC5cps 14.3 
Water q.s 
Magnesium stearate 2.4 
Total 297.2 
9. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step8 
10. Compressed the blend of Step 9 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
 
Formulation X2 
WET GRANULATION:  
 Table 7 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by wet granulation by X -2. 
 Composition of  the formulation X2 
Table :7 
 
 
 
 
 
 
 
 
 
 
Procedure: 
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in planetary mixer 
4. Prepared HPMC 5cps binder solution (Take 95 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
INGREDIENTS 
X-2 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 68.4 
MCC (AVICEL 102) 186.3 
HPMC5cps 13.2 
Water q.s 
Magnesium stearate 2.4 
Total 295.9 
6. Wet granules are formed 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step8 
10. Compressed the blend of Step 9 into round concave shaped tablets with the help 
of 8mm concave shaped punches. 
 
Formulation X3 
WET GRANULATION:  
Table 8 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by direct compression for  X -3 
 Composition of  the formulation X3 
Table : 8 
 
 
 
 
 
 
 
 
 
 
 
Procedure: 
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
INGREDIENTS X-3 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 122.4 
MCC (AVICEL 102) 132.2 
HPMC5cps 14.1 
Water q.s 
Mg.stearate 2.4 
Total 296.7 
3. That step 2 material is dry mixed for 20 min in planetary mixer 
4. Prepared HPMC 5cps binder solution (Take 95 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition of above solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step8 
10. Compressed the blend of Step 9 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
 
Formulation X4 
WET GRANULATION:  
 Table 9 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by wet granulation for X -4 
Composition of  theformulation X4 
Table :9 
 
 
 
 
 
 
 
 
 
 
 
INGREDIENTS X-4 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 221.6 
MCC (AVICEL 102) 35.7 
HPMC5cps 13.8 
Water q.s 
Mg.stearate 2.4 
Total 299.9 
Procedure: 
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in planetary mixer 
4. Prepared HPMC 5cps binder solution (Take 95 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition of above solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step8 
10. Compressed the blend of Step 9 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
Formulation X5 
WET GRANULATION:  
Table 10 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by wet granulation for X -5 
Composition of  the formulation  X5 
Table : 10 
 
 
 
 
 
 
 
 
 
INGREDIENTS X-5 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 221.6 
MCC (AVICEL 102) 35.7 
HPMC 5cps 13.8 
Water q.s 
Mg.stearate 2.4 
Total 299 
 Procedure: 
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 5Lt RMG(5000Tabs) 
4. Prepared HPMC 5cps binder solution (Take 150 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition of above binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (Up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step8 
10. Compressed the blend of Step 9 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
Formulation X6 
WET GRANULATION:  
Table 11 gives details of ingredients used in composition preparation of 
metoprolol succinate tablets by wet granulation for X-6 
Composition of  the formulation X6 
 
 
 
 
 
 
 
 
 
 
 
Table : 11 
 
 
 
 
 
 
 
 
 
 
 
Procedure: 
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 3Lt RMG(for 2000 tabs) 
4. Prepared HPMC 5cps binder solution (Take 150 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition of above binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step8 
10. Compressed the blend of Step 9 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
Formulation X7 
WET GRANULATION : 
INGREDIENTS X-6 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 229.2 
MCC (AVICEL 102) 24.3 
HPMC5cps 15.5 
Water q.s 
Mg.stearate 2.4 
Total 297 
Table 12 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by wet granulation for X-7 
Composition  of the formulation X7 
Table : 12 
 
 
 
 
 
 
 
 
 
 
Procedure:  
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 3Lt RMG(for 2000tabs) 
4. Prepared HPMC 5cps binder solution (Take 180 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition of above binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step8 
10. Compressed the blend of Step 9 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
 
INGREDIENTS 
 
X-7 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 122.2 
MCC (AVICEL 102) 132.1 
HPMC5cps 14.1 
Water q.s 
Mg.stearate 2.4 
Total 296.4 
Formulation X5 EGI 
WET GRANULATION : 
 Table13 gives details of ingredients used in composition preparation of 
metoprolol succinate tablets by wet granulation for X-5 EG – 1 
 Composition of the formulation X5 EG1 
Table :13 
 
 
 
 
 
 
 
 
 
 
 
Procedure:  
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 3Lt RMG(for 2000tabs) 
4. Prepared HPMC 5cps binder solution (Take 150 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition above binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular retardant through BSS # 40 and blended with material of 
step 8 
10. Sifted extra granular lubricant through BSS # 40 and blended with material of 
step 9 
INGREDIENTS X-5 EG-1 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 200.4 
MCC (AVICEL 102) 35.9 
HPMC5cps 13.8 
Water q.s 
HPMC K100M 21.1 
Mg.stearate 2.4 
Total 299.5 
11. Compressed the blend of step 10 in to round concave shaped tablets with the 
help of 8 mm concave shaped punches. 
 
Formulation X5 EG2 
WET GRANULATION:  
Table14givesdetailsofingredientsusedincompositionpreparationofmetoprololsuccina
tetabletswet granulation for X -5 EG-2 
   Composition of the  formulation X5 EG2 
Table : 14 
 
 
 
 
 
 
 
 
 
Procedure:  
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 3Lt RMG(for 2000tabs) 
4. Prepared HPMC 5cps binder solution (Take 150 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition above binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (Up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
INGREDIENTS X-5 EG-2 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 122.2 
MCC (AVICEL 102) 102.4 
HPMC5cps 14.1 
Water q.s 
HPMC K100M 30.5 
Mg.stearate 2.84 
Total 296.24 
9. Sifted extra granular retardant through BSS # 40 and blended with material of 
step8 
10. Sifted extra granular lubricant through BSS # 40 and blended with material of 
step 9 
11. Compressed the blend of Step10 into round concave shaped tablets with the 
help of 8mm concave shaped punches 
 
Formulation X7 EG1 
WET GRANULATION:  
 Table 15 gives details of ingredients used in composition preparation of  
metoprolol succinate tablets by wet granulation for X-7 EG-1 
Composition of  the formulation X7EG1 
Table :15 
 
 
 
 
 
 
 
 
 
Procedure:  
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 3Lt RMG(for 2000tabs) 
INGREDIENTS X-7 EG-1 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 68.4 
MCC (AVICEL 102) 186.2 
HPMC5cps 10.5 
Water q.s 
HPMC K100M 3.2 
Mg.stearate 2.4 
Total 295.8 
4. Prepared HPMC 5cps binder solution (Take 150 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition of  above binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (Up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular retardant through BSS # 40 and blended with material of 
Step8 
10. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step9 
11. Compressed the blend of Step10 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
Formulation X8 
WET GRANULATION:  
 Table 16 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by wet granulation for X-8 
Composition of the  formulation X8 
Table :16 
 
 
 
 
 
 
 
 
 
 
Procedure:  
1. Weighed all ingredients accurately  
INGREDIENTS X-8 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 204.3 
MCC (AVICEL 102) 32.5 
HPMC 5cps 16.6 
Water q.s 
HPMC K100M 19.2 
Mg.stearate 2.02 
Total 300.22 
 
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 3Lt RMG(for 2000tabs) 
4. Prepared HPMC 5cps binder solution (Take 150 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition of binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (up to LOD<2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular retardant through BSS # 40 and blended with material of 
Step8 
10. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step9 
 Compressed the blend of Step10 into round concave shaped tablets with the 
help of 8 mm concave shaped punches 
 
Formulation X9 
WET GRANULATION : 
 Table 17 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets  by wet granulation for X-9  
Compositions of the formulation X9 
Table : 17 
 
 
 
 
 
 
 
 
INGREDIENTS X-9 
mg/tab 
Metoprolol 
succinate 
25.6 
Xanthan gum 209.2 
MCC (AVICEL 
102) 
31.1 
HPMC5cps 16.4 
Water q.s 
HPMC K100M 18.2 
Mg.stearate 2.02 
Total 302.52 
 Procedure:  
1. Weighed all ingredients accurately  
2. Sifted metoprololsuccinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 3Lt RMG(for 2000tabs) 
4. Prepared HPMC 5cps binder solution (Take 150 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition of  above binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular retardant through BSS # 40 and blended with material of 
Step8 
10. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step9 
11. Compressed the blend of Step10 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
Formulation X8 T1 
WET GRANULATION:  
Table 18 gives details of ingredients used in composition preparation of metoprolol 
succinate tablets by wet granulation X-8 Trial-1 
Composition of the  formulation X8 T1 
 
 
 
 
 
 
 
 
 
Table :18 
 
 
 
 
 
 
 
 
 
 
Procedure:  
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 3Lt RMG(for 2000tabs) 
4. Prepared HPMC 5cps binder solution (Take 150 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition above binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (Up to LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular retardant through BSS # 40 and blended with material of 
Step8 
10. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step9 
11. Compressed the blend of Step10 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
Formulation X8 T2 
WET GRANULATION : 
 
INGREDIENTS 
X-8 trial-1 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 207.7 
MCC (AVICEL 102) 33.2 
HPMC 5cps 15.4 
Water q.s 
HPMC K100M 19.4 
Mg.stearate 2.02 
Total 303.02 
Table 19 gives details of ingredients used in composition preparation of 
metoprolol succinate tablets by wet granulation X-8 Trail-2 
Composition of the  formulation  X8 T2 
Table: 19 
 
 
 
 
 
 
 
 
 
 
 
Procedure:  
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in 3Lt RMG(for 2000tabs) 
4. Prepared HPMC 5cps binder solution (Take 150 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution added to dry mixed blend in 2-3 min 
6. Wet granules are formed by the addition of above binder solution 
7. Wet granules of Step 6 were dried at 60o C for 45 minutes. (upto LOD <2%) 
8. Sifted dried granules through BSS # 25 sieve 
9. Sifted extra granular retardant through BSS # 40 and blended with material of 
Step8 
INGREDIENTS X-8 trial-2 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 208.2 
MCC (AVICEL 102) 31.1 
HPMC5cps 16.4 
Water q.s 
HPMC K100M 18.2 
Mg.stearate 2.02 
Total 301.52 
10. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step9 
11. Compressed the blend of Step10 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
Formulation X10 
WET GRANULATION: 
Table 20 gives the details of ingredients used in composition preparation of 
metoprolol succinate tablets by wet granulation for X-10 
Composition of  the formulation  X10 
Table: 20 
 
 
 
 
 
 
 
 
 
 
Procedure: 
1. Weighed all ingredients accurately  
2. Sifted metoprolol succinate, polymer, diluents through #40 sieve  
3. That step 2 material is dry mixed for 20 min in FBC  
4. Prepared HPMC 5cps binder solution (Take 400 ml of water add HPMC 5cps 
slowly with continuous stirring) 
5. That step 4 binder solution slowly sprayed in blend  with the help of top spray 
at the conditions 
6. Wet granules are formed by the addition of above  binder solution 
7. Wet granules of Step 6 were dried at 60o C. (up to LOD<2%) 
8. Sifted dried granules through BSS # 25 sieve 
INGREDIENTS X-10 
mg/tab 
Metoprolol succinate 25.6 
Xanthan gum 207.6 
MCC (AVICEL 102) 32.3 
HPMC5cps 16.5 
Water q.s 
HPMC K100M 19.1 
Mg.stearate 2.02 
Total 304.4 
9. Sifted extra granular retardant through BSS # 40 and blended with material of 
Step8 
10. Sifted extra granular lubricant through BSS # 40 and blended with material of 
Step9 
11. Compressed the blend of Step10 into round concave shaped tablets with the 
help of 8mm concave shaped punches. 
 
 
6.5.EVALUATION OF MATRIX TABLETS: 
 The prepared matrix tablets were evaluated for General appearance, 
thickness, hardness, weight variation, friability and drug content.  
General appearance: 
 The tablets prepared were white, round, spherical shape. They were smooth, 
uniform and free from cracking and chipping 
Hardness test  
 Hardness (diametric crushing strength) is a force required to break a tablet 
across the diameter. The hardness of a tablet is an indication of its strength. The 
tablet should be stable to mechanical stress during handling and transportation. The 
degree of hardness varies with the different manufactures and with the different 
types of tablets. The permissible limit for hardness is 4-12kg/cm
2
. The hardness was 
tested using Monsanto tester. “Hardness factor”, the average of the ten 
determinations was determined and reported. The results are shown in the table: 24 
Uniformity of weight (Weight variation test): 
 This is an important In-process quality control test to be checked frequently 
(every half an hour). Corrections were made during the compression of tablets. Any 
variation in the weight of tablet (for any reason) leads to either under medication or 
overdose. So, every tablet in each batch should have a uniform weight. 20 tablets 
were weighed individually.  Average weight was calculated from the total weight of 
all tablets.  The individual weights were compared with the average weight. The 
percentage difference in the weight variation should be within the permissible limits 
(7.5%). The percent deviation was calculated using the following formula. The 
limits are mentioned in the below table as per Indian pharmacopoeia (I.P). The 
results are shown in the table: 24 
   Individual weight – Average weight 
                  % Deviation =                                                             x 100  
                  Average weight 
 
 
 
 
 
 
 
Friability test: 
 Friability is the loss of weight of tablet in the container/package, due to 
removal of fine particles from the surface. This In-process quality control test is 
performed to ensure the ability of tablets to withstand the shocks during processing, 
handling, transportation, and shipment. Roche friabilator was used to measure the 
friability of the tablets.  It was rotated at a rate of 25 rpm.  Five tablets were weighed 
collectively and placed in the chamber of the friabilator.  In the friabilator, the 
tablets were exposed to rolling, resulting from free fall of tablets within the chamber 
of the friabilator.  After 100 rotations (i.e. in 4 minutes), the tablets were taken out 
from the friabilator and intact tablets were again weighed collectively.  Permitted 
friability limit is 1.0%. The percent friability was determined using the following 
formula The results are shown in the table: 24 
   (W1 – W2)/W1    × 100             
  Average weight  Percent difference 
130 mg or less  10 
More than 130 mg but less than 324 mg  7.5 
More than 324 mg  5 
      Where,  
       W1 =     weight of the tablets before test 
  W2 =     weight of the tablets after test 
Content of active ingredient 
 To ensure the consistency of dosage units, each unit in a batch should have 
active substance content within a narrow range around the label claim. Dosage units 
are defined as dosage forms containing a single dose or a part of a dose of an active 
substance in each dosage unit. 
 Ten tablets from each formulation were powdered. The powder equivalent to 
50 mg of metoprolol was weighed and dissolved in 5 ml of water and 60 ml of 
methanol in 200  ml standard flask Shaken for 30 min and then made up with 0.1N 
Hcl and then centrifuge . 5  ml of this solution in 50  ml standard flask was made up 
with mobile phase AS per procedure given below generally; the drug content in any 
formulation should fall within the limit of 90 – 110%. Ref  USP vol 3 
6.6 ESTIMATION  OF METOPROLOL SUCCINATE: 
Mobile Phase :   
(1) Mix pH 3.0 buffer solution and Acetonitrile in the ratio of  75 : 25 respectively. 
(2) Degas in a sonicator for about 10 minutes. 
Standard Preparation:  
Transfer about 12 mg of Metoprolol succinate working standard, accurately weighed 
to a 100  ml volumetric flask ,and add 50 ml of pH 6.8 phosphate buffer, dissolve in 
and dilute to volume with mobile phase. (1)  Pipette 5  ml of the above 
Standard stock solution into a 50  ml volumetric flask and  
 (1)  Pipette 1  ml of the above Standard stock solution into a 10  ml volumetric flask  
and dilute to volume with dissolution medium pH6.8 phosphate buffer and mix.      
Chromatographic System : 
(1) The liquid Chromatographic system is  equipped with a 280-nm UV detector.  
(2)    Column :  4.6-mm  x  150-mm  column  that  contains 5 µm packing 
octylsilane 
 chemically  bonded   to  porous silica  or  ceramic  micro-particles,(4.6-mm x 
150-mm, Xterra RP8, 5µm or equivalent). 
 
(3) Column temperature : Ambient 
(4) Flow rate  : 1.0   ml per minute. 
 
 
System suitability: 
(1)  Inject 40 µL portion of the Standard preparation into chromatographic system 
for five times, record the record the chromotogram and measure the response for 
major peak. 
 (a)   Tailing factor for Metoprolol Succinate peak should be not more than 2.0  
 (b)   The relative standard deviation for peak areas of  Metoprolol Succinate 
for five 
 Replicate injections should be not more than 2.0 % 
 Procedure:  
 Inject 40 µL portion of the dissolution medium as blank, standard preparation 
for five times, test preparation into the chromatograph, record the chromatogram and 
measure the responses  for major peaks  
Calculations:  
Quantity of Metoprolol Succinate dissolved in n th time interval as % of labeled 
amount.     
An x Ws x 5 x P x 500 x 100 
Dn = ------------------------------------- 
                                                           As x 100 x 100 x  100 x L 
Where:-   
An = Peak area of Metoprolol Succinate for Test preparation, in n th time interval. 
AS = Peak area of Metoprolol Succinate for Standard preparation. Ws = Weight of Metoprolol Succinate standard taken, in mg, for Standard preparation. 
P = Potency of Metoprolol Succinate Standard calculated as Metoprolol Succinate. 
L = Labeled amount of Metoprolol Succinate in mg, per Tablet. 
    
Calculation of Correction factors:  
% of Metoprolol succinate present in sample  volume after 1
st
 time interval, 
F1= (D1 / 900)x10 
% of Metoprolol succinate present in sample  volume after 2
nd
 time interval, 
F2= (D2 / 900)x10 
% of Metoprolol succinate present in sample  volume after 3
rd
 time interval, 
F3= (D3 / 900)x10 
% of Metoprololsucciante present in sampled volume after 4
th
 time interval, 
F4= (D4 / 900) x10 
Calculation of Corrected results:   
For 1
st
 time interval    = D1 (No correction required).  
For 2
nd 
time interval    = D2 + F1  
For 3
rd 
time interval    = D3 + F1 + F2  
For 4
th
 time interval    = D4 + F1 +F2 + F3 
6.7 ASSAY:
 
Reagents:  
 
Preparation Buffer solution:    
(1)   Dissolve about 6.9 g of Sodium dihydrogen phosphate monohydrate   in 1000  
ml of Milli-Q-water and mix.      
(2)  Adjust the pH of the solution to 3.0 with Orthophosphoric acid.    
(3)  Filter the above solution through 0.45µm DuraporeHydrophyllic membrane 
filter. 
Mobile phase:          
Mix Buffer and Acetonitrile in the ratio of 75: 25.Degas in a sonicator for 10 
minutes. 
Standard Preparation:          
(1) Transfer about 95 mg of Metoprolol succinate reference standard or working 
standard,  
Accurately weighed to a 100- ml volumetric flask.  Dissolve and dilute to volume 
with mobile phase and mix.    
(2)  Pipette 5  ml of above solution into a 100  ml volumetric flask, dilute to volume 
with Mobile phase and mix.         
(3)  Filter through 0.45µm M D I Nylol-66 membrane filter 
Test Preparation:   
(1) Transfer an accurately weighed amount of 260 mg of matrix tablet crushed 
powder in to a 100 ml volumetric flask 
(2) Add about 5 ml of water shake the flask for 2 minutes to disintegrate, and add 30 
ml of ethanol and shake for 30 minutes on rotary shaker and add about 40 ml of 
0.1N Hydrochloric acid and keep on a rotary shaker for 30 minutes. 
(3) Dilute to volume with 0.1N Hydrochloric acid and mix.     
(4)   Centrifuge the above solution with cap at 4000 rpm for about 10 minutes. 
(5)   Pipette 5  ml of the above clear centrifugate into a 50  ml volumetric flask, 
dilute   to volume with mobile phase and mix.      
 (6)  Filter about 2  ml  through  0.45µm membrane filter . 
Chromatographic System:        
(1)    Detector: Liquid Chromatographic system equipped with UV Visible detector 
at 280 nm 
(2)    Column:  4.6-mm x 150mm column that contains packing octylsilane 
Chemically bonded   to porous silica, 3 to 10 µm in diameter.(4.6-mm x                                                               
150-mm, Xterra RP 8, 5µ or equivalent).    
(3)    Column temperature: Ambient      
(4)    Flow rate: 0.8  ml per minute. 
System suitability: 
(1)  Inject 40 µL portion of the Standard preparation into chromatographic system 
for five times, record the record the chromatogram and measure the response for 
major peak. 
(2)   Tailing factor for Metoprolol Succinate peak should be not more than 2.0  
(3)   The relative standard deviation for peak areas of Metoprolol Succinate for five  
        Replicate injections should be not more than 2.0 % 
Procedure:          
Inject 40µL portion of the mobile phase and test preparation into the chromatograph, 
Record the chromatogram and measure the peaks response. 
Calculations:    
Quantity of Metoprolol succinate present in portion of ER Tablet as % of labeled 
amount      
    A x Ws x 5 x P x 500  x 100 x  1000 x 100  
   =   --------------------------------------------------------     S x 100 x 100 x 100  xWt x 5 x L    
 
 A   = Peak area of Metoprolol succinate for test preparation.  S   = Peak area of Metoprolol succinate for Standard preparation.  Ws = Weight of Metoprolol succinate standard taken, in mg. 
 P = Potency of Metoprolol succinate Standard calculated as 
Metoprolol   succinate. 
          Wt = Weight of pellets taken, in “mg” for test preparation. 
           L = Labeled claim of metoprolol succinate per gram. 
 
 
6.8.In-vitro drug release studies: 
 In-vitro drug release studies were carried out using USP XXIV 
dissolution  apparatus   type II, with  900  ml of dissolution medium maintained at 
37±0.5°C for 20 hrs, at 100 rpm,   pH 6.8 ±0.2 phosphate buffer as dissolution 
medium. 
 Sample was withdrawn at predetermined time intervals replacing with an 
equal quantity of drug free dissolution fluid. The samples withdrawn were filtered 
through 0.45µ membrane filter, and concentration of drug in each sample was 
analyzed by HPLC at 280 nm and cumulative percent drug release was calculated. 
The study was performed in triplicate .The commercial Toprol XL tablets were used 
as the reference formulation, and were also subjected to In-vitro drug release studies 
The results of In-vitro release profile obtained for all the formulations were plotted 
in modes of data treatment as follows. 
 1.  Log cumulative percent drug remaining versus time (firstorder kinetic 
model)  
 2.  Cumulative percent drug release versus square root of time (Higuchis 
model)  
 3.  Cumulative percent drug release versus time (zero order kinetic model)  
 4.  Log cumulative Percent Drug released versus log time (korsmeyers 
model) 
Drug release kinetics-model fitting of the dissolution Data: 
Whenever a new solid dosage form is developed or produces, it is necessary 
to ensure that drug dissolution occurs in an appropriate manner. Nowadays the 
pharmaceutical industry and the registration authorities focus on drug dissolution 
studies. Drug dissolution from solid dosage forms has been described by kinetic 
models in which the dissolved amount of drug (Q) is a function of the test time, t or 
Q = f (t). Some analytical definitions of the Q (t) function are commonly used such 
as zero order, first order, Higuchi, korsmeyers models. Other release parameters, 
such as dissolution time (tx%), dissolution efficacy (ED), difference factor (f1), 
similarity factor (f2) can be used to characterize drug dissolution / release profile.  
 
Zero-order kinetics :       
A zero-order release would be predicted by the following equation.  
                                       At    =   Ao- Kot         …………. 1 
Where  
  At    =    Drug release at time t 
  Ao   =     Initial drug concentration 
  Ko   =     Zero-order rate constant (hr) 
                 When the data is plotted as cumulative percent drug release versus time  if 
the plot is linear then the data obeys zero-order release kinetics, with a slope equal to 
ko. 
Use:   
This relation can be used to describe the drug dissolution of several types of 
modified release pharmaceutical dosage forms, as in case of some transderrmal 
systems etc. the pharmaceutical dosage forms following this profile release the same 
amount of drug by unit of time and it is the ideal method of drug release in order to 
achieve a prolonged pharmacological action. 
First-order kinetics: 
A first order release would be predicted by the following equation. 
   Log C    =      Log Co -  Kt / 2.303   2 
Where 
   C    =   Amount of drug remained at time t 
   Co  =   Initial amount of drug 
   K    =    First-order rate constant 
When the data is plotted as log cumulative percent drug remaining versus 
time yields a straight line indicating the release follows first-order kinetics, the 
constant k can be obtained by multiplying 2.303 with slope values 
Use:  
 The pharmaceutical dosage forms containing water-soluble drugs in porous 
matrices, follows this type of dissolution profile. The release of the drug is 
proportional to the amount of drug remaining in its interior so that the amount of 
drug release by unit of time diminishes 
Higuchimodel:  
Drug release from the matrix devices by diffusion has been described by 
following Higuchis classical diffusion equation. 
     Q = [DE/ τ(2A- ECs) Cst ]               ………………  3 
Where 
  Q   =   Amount of drug release at time t 
  D   =   Diffusion coefficient of the drug in the matrix 
  A    =   Total amount of drug in unit volume of matrix 
  Cs   =   The solubility of the drug in the matrix 
  E     =   Porosity of the matrix 
  T     =   Time in hrs at which q is the amount of drug is release 
                Equation-3 may be simplified if one assumes that D, Cs and A are 
constant.  Then equation-3 becomes 
                                 
   Q    =    K t ½ 
When the data is plotted according to equation-4 i.e. cumulative drug release versus 
Square root of time yields a straight line, indicating that the drug was released by 
diffusion mechanism. The slope is equal to k. 
Use:  
The relation can be used to describe the drug dissolution from several types 
of modified release pharmaceutical dosage forms, as in case of some water soluble 
drugs. 
K In order to understand the mode of release of drug from swell able 
matrices, the data were fitted to the following equation   
   Mt    /    Mά         = Kt
n
 
Where, 
  Mt / Mά  =      The fraction of drug released at time „t‟ 
  K  =      Constant incorporating the structural and 
geometrical       Characteristics of the drug / 
polymer system. 
  n  =      Diffusion exponent related to the mechanism of release. 
The above equation can be simplified by applying log on both sides we get  
Log       Mt  /   Mά             =     Log K+ n Log t         
When the data is plotted as a log of drug released versus log time, yields a 
straight line with a slope equal to n and the k can be obtained from y- intercept. 
The value of n for a cylinder is <0.45 for Fickian release,  > 0.45 and < 0.89 for non-
Fickian release, 0.89 for the case 2 release and > 0.89 for  super case2 type 
release.The results are shown in the table 25. 
 
 
 
6.9 DISSOLUTION: 
a. Selection of method: 
Metoprolol succinate was formulated by using three methods namely direct 
compression, dry granulation and wet granulation.  
           In these three methods direct and dry granulation tablet surface was not 
smooth sticking problem was there, in wet granulation tablet no sticking problem 
was there so I selected wet granulation. 
b. Selection of polymer concentation: 
Metoprolol succinate formulated by using in 4 different concentrations of xanthan 
gum i,e 30%,35%,50%,70%(X-1A, X-2, X-3, X-4) 
 
6.10.STABILITY STUDIES 
Optimized formulation was charged for two months as accelerated stability 
conditions at 40
0
C/75% RH. The samples kept at 40
0
C/75% RH were compared 
with control samples for every month. In-vitro evaluation, assay, physical 
parameters were compared. Those results were as follows in the table 43 & 44.  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
RESULTS AND DISSCUSIONS 
 
 
 
 
 
 
 
7.1 Fourier Transform Infrared Spectroscopy:  
 Infrared spectra matching approach was used for the detection of any 
possible chemical reaction between the drug and the polymer. A physical mixture 
(1:1) of drug and polymer was prepared and mixed with suitable quanta of 
potassium   bromide. About 100 mg of this mixture was compressed to from a 
transparent pellet using a hydraulic press at 10 tons pressure. It was scanned from 
4000 to 400 cm
-1
 in a Shimadzu FTIR 8400 Spectrophotometer. The IR spectrum of 
the physical mixture was done to detect any appearance or disappearance of peaks. 
 
  
Fig.7:FTIR OF METOPROLOL SUCCINATE + STD+ 
HPMC 
  
Fig. 8: FTIR OF METOPROLOL SUCCINATE +STD +HPMC K 
100M 
 Fig.9 :FTIR OF METOPROLOL SUCCINATE +STANDARD 
 
  
Fig .10: FTIR OF METOPROLOL SUCCINATE +HPMC 
 
  
 
FIG .11: FTIR OF METOPROLOL SUCCINATE +MCC 
  
Fig .12:FTIR  METOPROLOL SUCCINATE SAMPLE 
 7.2 PREFORMULATION RESULTS: 
Table: 22 
Formulation Bulk 
density 
(gm/ ml) 
Tapped 
density ( 
gm/ ml) 
Compressibility 
index ( %) 
Hausner’s 
ratio 
X1A 0.350 0.384 7.69 1.075 
X1B 0.344 0.352 5.18 1.065 
X1C 0.372 0.345 6.32 1.075 
X2 0.435 0.376 8.03 1.082 
X3 0.461 0.377 9.23 1.064 
X4 0.365 0.354 7.018.65 1.076 
X5 0.485 0.363 8.06 1.054 
X6 0.431 0.371 5.62 1.062 
X7 0.421 0.363 7.18 1.077 
X5 EG1 0.370 0.374 5.17 1.068 
X5 EG2 0.352 0.383 6.85 1.056 
X7 EG1 0.361 0.372 6.58 1.071 
X8 0.352 0.384 8.08 1.059 
X9 0.360 0.3654 6.62 1.063 
X8 T1 0.352 0.387 8.17 1.062 
X8 T2 0.432 0.386 9.98 1.075 
X10 0362 0.378 7.45 1.065 
 
 
 
 
 7.3 Flow properties of API 
Table 23:  
 
S.N
O 
W 
(gm) 
V0 
( 
ml) 
V 
( ml) 
Bulk density 
(gm/ ml) 
Tapped 
density 
(gm/ ml) 
Compressibility 
index* 
[1-V/V0] *100 
Hausner’ s 
Ratio# 
[T.D/B.D] 
1 20.00 56 52 0.357 0.384 7.69 1.075 
2 20.00 57 53 0.350 0.377 7.01 1.076 
3 20.00 58 55 0.344 0.363 5.17 1.05 
Avg. 20.00 57 53.3 0.350 0.374 6.62 1.06 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
7.4 Evaluation of Matrix Tablets 
TABLE 24:   
 
Formulations Weight(mg) Thickness(mm) Hardness(kp) Friability(%) Assay(%) 
X1A 297 4.3 -4.4 6.8 1.08 100.2 
X1B 297.9 4.3 -4.4 6.8 1.02 101 
X1C 297.2 4.2 -4.3 12.2 0.09 99.63 
X2 295.9 4.3 -4.4 11 0.07 101.2 
X3 296.7 4.4 -4.5 9.6 1.02 102 
X4 299.9 4.5 -4.6 8.5 1.06 100.1 
X6 297 4.3 -4.4 7.5 1.03 99.8 
X7 296.4 4.3 -4.4 9.6 1.02 102.2 
X5 EG1 299.5 4.4 -4.5 6 1.08 99.23 
X5 EG2 296.24 4.4 -4.5 5.7 1.05 100.4 
X7 EG1 295.8 4.3 -4.4 6.9 1.02 100.4 
X8 312.22 4.6 -4.7 7.8 0.09 100.6 
X9 311.52 4.5 -4.6 6.8 1.02 101.7 
X8 T1 312.02 4.9 -5.0 8.9 1.07 102.2 
X8 T2 311.52 4.8 -4.9 7.6 1.05 100.3 
X10 312.4 4.4 -4.5 5.5 1.06 100.1 
 
  
7.5 ESTIMATION OF RELEASE MECHANISMS BY MATHAMETICAL 
MODELS 
The rate of release of metoprolol succinate was calculated using data fitting method 
for X8 formulation and results are as follows 
Table 25: Release mechanism by mathematical models 
Release mechanism Values 
Zero – order(r) 0.9349 
First order(r) 0.9987 
Higuchi(r) 0.9943 
Peppas(n) 0.6845 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
7.6 Dissolution 
In-vitro Evaluation: 
Table 26 :  %  Cumulative drug release of  metoprolol succinate extended release 
matrix tablets at different concentrations of xanthan gum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time in 
hrs 
Cumulative %drug release 
X-1A X-2 X-3 X-4 Marketed 
sample 
1hr 20 18 13 11 10 
4hr 49 42 34 31 29 
8hr 75 64 56 51 49 
20hr 102 92 88 82 84 
  
 
 
 
Fig 13 shows % Cumulative drug release of metoprolol succinate from 
 
 
From the above results  for the formulation of matrix formulation , 50% and 70% 
xanthan gum formula are choosen, because that two formulations results nearer to 
marketed sample. 
 
  
 
 
 
Effect of Extra Granular: 
Table 27: % Cumulative drug release of Metoprolol succinate extended release 
matrix tablets at different  extra granular concentrations of below formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time in 
hrs 
Cumulative %drug release 
X-5 X-5 
EG-1 
X-5 
EG-2 
X-7 X-7 
EG-1 
Marketed 
sample 
1 20 18 13 15 14 10 
4 49 42 34 38 36 29 
8 75 64 56 62 60 49 
20 102 92 88 100 97 84 
  
 
 
 
 
 
 
 
Fig 14 shows% Cumulative drug release of  metoprolol succinate from 
 
 
From the above results conclusion is extra granular concentration and dissolution 
profile is directly proportional so, in the next trials extra granular is added.  
 
 
 
 
 
 
 
Effect of particle size: 
Table 28 : % Cumulative drug release of Metoprolol succinate extended release 
matrix tablets at different particle size of the granules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
Cumulative %drug release 
X-6 
 
Marketed 
sample 
#25 
1 16 10 
4 41 29 
8 66 49 
20 103 84 
  
 
       
 
Fig :15 shows % Cumulative drug release  of Metoprolol succinate from 
 
From the above dissolution result particle size of the formulation does  not vary the 
dissolution result, so in this  #25 mesh is selected for all the formulations. 
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Optimization of formula: 
Table 29 : % Cumulative drug release of  Metoprolol succinate extended release 
matrix tablets with extra granulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time in hrs 
Cumulative %drug release 
 
X-8 X-9 
Marketed 
sample 
1 12 12 10 
4 33 32 29 
8 54 52 49 
20 90 88 84 
  
 
 
Fig 15 shows % Cumulative drug release of Metoprolol succinate  from 
 
From the above dissolution results X-8,X-9 formulas matches with marketed sample 
so in this X-8 formula taken and seen the reproducibility of the batch. 
 
 
 
 
 
 
  
 
Reproducibility batches: 
Table 30:  %  Cumulative drug release of metoprolol succinate extended release 
matrix tablets for reproducibility batches 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time in hrs 
Cumulative %drug release 
 
X-8 Trial-1 X-8 trial-2 
Marketed 
sample 
1 14 14 10 
4 34 35 29 
8 54 56 49 
20  89 91 84 
  
 
 
 
 
Fig 16 shows % Cumulative drug release of  metoprolol succinate from 
 
Reproducibility batches result is also very good, but in the RMG granules was very 
hard , at the time of shifting it has problem so , one trial in FBC with same formula  
was performed 
 
 
  
 
 
 
 
FBC batch: 
Table 31:  %  Cumulative drug release of  metoprolol succinate extended release 
matrix tablets for FBC batch. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
Cumulative %drug release 
X-10 
Marketed 
sample 
1 14 10 
4 34 29 
8 54 49 
20 85 84 
  
 
 
 
 
 
 
Fig 17 shows % Cumulative drug release of  metoprolol succinate from 
 
From the above FBC process results showing pharmaceutical equivalence product. 
And also overcome the hard granules problem faced in RMG process. This FBC 
process is also very easy and given a pharmaceutical equivalent product 
 
7.7 Assay method validation:  
1. System suitability and precision: 
 The standard solution prepared by using Metoprolol succinate working 
standards as per the test method and injected six times into HPLC system. The 
system suitability parameters were evaluated and found to be within the limits. The 
RSD for peak areas from five replicate injections of Metoprolol was found to be 
within limits .The RSD for peak areas from five replicate injections of Metoprolol 
was found to be 0.1%, and the tailing factor of Metoprolol is found to be 1.3. 
Table 32: System precision and system suitability 
 
 
 
 
Injection number Metoprolol succinate 
ASSAY 
1 1243450 
2 1245626 
3 1243983 
4 1243172 
5 1241181 
Mean 1243482 
%RSD 0.1 
  
 
2 .Linearity: 
 A graph is plotted to “concentration” versus “area” in linearity section. The 
correlation coefficient was found to be 0.99964 for Metoprolol. From the above 
study it was established that the detector linearity is from 25% to 150% of the 
labeled amount of Metoprolol Succinate tablets. 
Table 33: Linearity of detector response 
 
 
 
 
 
 
 
3.Specificity(placebo interference): 
  A study of placebo interference from excipients was conducted. Placebo 
interference checked by taking about 565mg of placebo in 250  ml of volumetric 
flask in triplicate, equivalent to about the weight of placebo as per the test method. 
There is no interference at RT of Metoprolol peak. 
 
System suitability Observed value Acceptance criteria 
The tailing factor for 
Metoprolol 
1.3 NMT 2.0 
Standard concentration Area 
25% 298146 
50% 622976 
75% 940316 
100% 1239674 
125% 1580572 
150% 1847581 
Coefficient of correlation(r) 0.999644 
Table34 : Placebo interference 
 
 
 
 
 
4.Precision: 
 The precision of test procedure was evaluated for Metoprolol tablets by 
performing the assay and content uniformity as per the test method. The % relative 
standard deviation recovery of Metoprolol was found to be within the limits.  
Table 35: Repeatability 
 
 
 
 
 
 
 
 
5.Accuracy: 
 A study was conducted. Drug assy was performed in triplicate by spiking 
with equivalent amount of Metoprolol raw material into each volumetric flask for 
each spike level to get the concentration of Metoprolol equivalent to 
25%,50%,75%,100%,125% and 150% of the labeled amount of metoprolol as per 
Sample no. 
%interference found 
Tablets 
1 Nil 
2 Nil 
3 Nil 
Sample no. % drug recovered 
1 99.23 
2 99.28 
3 98.40 
4 97.97 
5 98.68 
6 98.57 
7 98.69 
8 0.5 
the test method. The average % recovery of Metoprolol was found to be within the 
limits. 
Table 36: Accuracy 
 
 
 
 
Sample No. Spike Level 
Amount 
Added(Ppm) 
Amount 
Found(Ppm) 
Mean% 
Recovery 
1 25% 11.875 11.87 
100.16 2 25% 11.875 12.01 
3 25% 11.875 11.78 
4 50% 23.75 23.64 
99.53 5 50% 23.75 23.81 
6 50% 23.75 23.46 
7 75% 35.625 35.62 
100.01 8 75% 35.625 35.80 
9 75% 35.625 35.45 
10 100% 47.5 47.55 
100.11 11 100% 47.5 47.69 
12 100% 47.5 47.50 
13 125% 59.375 59.20 
99.71 14 125% 59.375 59.08 
15 125% 59.375 59.32 
16 150% 71.25 71.12 
99.82 17 150% 71.25 71.05 
18 150% 71.25 71.19 
6.Linearity of test method: 
 A graph is plotted to “amount of Metoprolol added” Versus “amount of 
Metoprolol found” in accuracy section. The correlation coefficient was found to be 
0.999995. From the above study it was established that the linearity of test method is 
from 25% to 150% of the labeled amount of Metoprolol. 
Table 37: Linearity of test method 
 
 
7.Ruggedness: 
i) Bench top stability of standard and test preparations: 
 The bench top stability of Metoprolol in standard and test preparation 
was established over a period of about 2 days. Both standard and test 
preparations were stored on bench top and analyzed at Initial, 1day and 2day 
against a freshly prepared standard each time. The difference in %assay of 
standard and test preparation from initial to 2days was found to be within the 
limits. The standard and test preparations are stable up to 48hrs 
 From the above study, it was established that Metoprolol in standard 
and test preparations was stable for a period of 48hrs 
 
Spike level in % Amount added Amount found 
25% 11.875 11.89 
50% 23.75 23.64 
75% 35.625 35.62 
100% 47.5 47.58 
125% 59.375 59.2 
150% 71.25 71.12 
Table 38:Ruggedness- Bench top stability of standard and test preparations 
 
8.Robustness: 
i) Effect of mobile phase composite variation: 
 By changing the composition of organic phase from 90% to 110% of 
organic phase robustness of dissolution method was checked, by injecting 
the five replicate injections of standard in 90% and 110% of organic phase 
composition. The system suitability parameter of Metoprolol standard is 
found within the limits. The method has been found to be robust from the 
90% to 110% of organic phase composition in mobile phase.  
 
 
 
 
 
 
Time In 
Days 
% Of 
Standard 
Preparation 
Difference 
From Initial 
%Assay Of 
Test 
Preparation 
Difference 
Test-
1 
Test-2 
Test-
1 
Test-
2 
Initial 99.39 NA 100.7 100.3 NA NA 
24hrs 98.65 0.74 101.9 102.69 1.2 2.39 
48hrs 99.71 0.32 98.9 98.3 1.8 2.0 
Table 39:.Robustness-Effect of variation in composition of organic phase in mobile 
phase 
System suitability 
parameters 
Observed value 
Acceptance 
criteria 
90% of method 
of organic 
phase 
100% 
method of 
organic 
phase 
110% of 
method of 
organic phase 
Tailing factor of 
Metoprolol peak in 
standard 
1.3 1.23 1.25 NMT 2.0 
%RSD of standard 
Metoprolol peak 
0.1 0.21 0.20 NMT 2.0 
 
ii) Effect of flow rate variation:  
 Robustness of the method as checked by changing the flow rate from 
0.8 ml/min to 1.2 ml/min instead of 1.0 ml/min by injecting the five replicate 
injections of standard in 0.8 ml/min and 1.2 ml/min flow rate. The system 
suitability parameter of Metoprolol standard is found within the limits. The 
method has been found to be robust from the flow rate 0.8 mlto 1.2 ml per 
min.  
Table 40. Robustness- Effect of variation in flow rate 
System suitability 
parameters 
Observed value 
Acceptances criteria 0.8 
ml/min 
1.0 
ml/min 
1.2 
ml/min 
Tailing factor of 
Metoprolol peak in 
standard 
1.3 1.25 1.31 NMT 2.0 
%RSD of standard 
Metoprolol peak 
0.2 0.1 0.3 NMT2.0 
 iii) Effect of column temperature variation: 
 Robustness of the method was checked by changing the column 
temperature at 200c and 300Cinstead of 250C by injecting the six replicate 
injections of standard at 200C and 300C. The system suitability parameters 
of metoprolol standard is found within the limits. The method has been 
found to be robust from the 200C to 300C.  
Table 41: Robustness-Effect of variation in column temperature 
System suitability 
parameters 
Observed value 
Acceptances criteria 
200C 250C 300C 
Tailing factor of 
Metoprolol peak in 
standard 
1.23 1.3 1.32 NMT 2.0 
%RSD of standard 
Metoprolol peak 
0.12 0.16 0.11 NMT 2.0 
iv) Effect of buffer: 
 Robustness of the method was checked by changing the buffer pH 
from 3.4-3.8 instead of 3.6 by injecting the five replicate injections of 
standard in 3.4pH and 3.8pH. The system suitability parameters of 
metoprolol standard is found within the limits. The method has been found to 
be robust from the buffer pH3.4 to buffer pH 3.8.  
 
 
 
 
Table 42: Robustness – Effect of variation in pH of buffer 
System suitability 
parameters 
Observed value 
Acceptances criteria 
pH3.4 pH3.6 pH3.8 
Tailing factor of 
Metoprolol peak in 
standard 
1.32 1.23 1.33 NMT 2.0 
%RSD of standard 
metoprolol peak 
0.12 0.11 0.13 NMT 2.0 
 
 
 
7.8 Stability studies 
Cumulative % release of stability studies of optimized formulation  
Table 43: 
 
 
 
 
 
 
 
  The samples analysed at initial stage and after one month and after two months at 
accelerated stage. 
 
 
 
 
Cumulative % drug 
release  
Time 
(Hr) Initial One month Two months 
1 14 14 14 
4 34 35 37 
20 55 56 57 
24 89 87 85 
Physical evaluation of tablet blend and optimization of stability 
formulations  
 
Table 44 : 
 
 
 
 
 
 
 
 
 
 
 
7.9 DISSCUSSION 
 The IR spectra of the pure drug and mixed drug samples with excipients are 
shown in Fig 7 to12. 
 Results obtained from the spectra showed that under stressed conditions the 
polymers does not influence any interaction with the drug. All the functional groups 
assigned in the wave numbers in all the different polymer mixtures exhibited 
maxima which are around the same wavelength and had similar intensities to that of 
the reference spectrum. 
Preformulation studies of drug were performed to characterize the 
metoprolol succinate. The powder flow properties of metoprolol succinate was 
studied to evaluate compressibility of the metoprolol succinate, since it has to be 
formulated as tablet. The results obtained are bulk density 0.328 mg/ ml and tapped 
density was 0.345mg/ ml and Hausner‟s ratio 1.05. The results showed that the 
 Initial One month Two months 
Color 
Cream 
orWhite 
Cream or 
White Cream or White 
Surface Smooth Smooth Smooth 
Thickness 4.8-4.9 4.8-4.9 4.8-4.9 
Hardness 8.5-9 8.5-9 8.5-9 
Assay 100.8 100.6 100.5 
compressibility of metoprolol succinate which indicates that the metoprolol 
succinate has excellent flow properties. 
Flow property of drug was good but direct compression method cannot be 
employed to formulate tablets, because of sticking problem, and also direct 
compression couldn‟t  retard the drug release because the drug is highly soluble. So 
wet granulation method was followed.  
The drug solution was prepared in 6.8 buffer and scanned using UV-
Spectrophotometer in the stage of 400 – 200 nm  to determine the λ max. The λ max 
of metoprolol succinate was found to be at 223 nm. But metoprolol succinate has 
placebo interaction. So,  HPLC method was followed. 
 Assay method was developed to analyze the content of drug in the tablet. 
The method was validated through Precision, System suitability, linearity, 
specificity, precision, accuracy, Linearity of test method, Ruggedness, Robustness. 
Accuracy of assay method was established by recovery experiment. 
Recovery of metoprolol at the concentration range of 25% to 150% was in range of 
99.53 – 100.16% which was acceptable. 
The precision of an analytical method is usually expressed as the Relative 
standard deviation (RSD) which should NMT 2%. The RSD of the method was 
determined to be in the range of 0.3-1.0 which is acceptable. 
Specificity was also acceptable as there is negligible interference. 
Linearity of metoprolol was taken from standard curve for which the 
correlation coefficient was 0.9996, which was acceptable. The concentration range 
for linearity was found between 25%  to 150%. 
Formulation X-8 was seemed to be close to the innovator‟s release profile. 
Then similarity factor was calculated between formulation X-8 and innovator. 
Similarity factor was 80, so formulation X-8 has similar release profile to the 
marketed formulation release. 
Accelerated stability studies of the optimized formulation were done at 
40
0
C and 75% RH for two months. It was seen that physically there was no change 
with respect to appearance, hardness, thickness and drug content. The dissolution 
profiles of one month and two months was similar when compared to dissolution 
profile at initial stage. This indicate that the formulation was stable at 40
0
C and 75% 
RH for two months.     
The dissolution profiles of optimized formulations were assessed for the 
release mechanism. The mathematical modelling of the profile into the drug release 
follows first order release. The value of “n” was 0.68 i.e. it was showing anomalous 
transport. 
Metoprolol succinate was formulated by using  direct compression, dry 
granulation, wet granulation. From all of these only wet granulation process has no 
tablet sticking problem so this is the preferred method. 
It was found that only formulation X8 and  X9 were statiscally similar to 
the marketed product. 
X9 was carried out using RMG process which showed sticking problems. 
Hence formulation X8 was chosen as the best formulation. 
Stability  studies show that the product is stable under accelerated testing 
conditions 
 
 
 
 
 
 
 
 
8. CONCLUSION 
 It may be concluded from the present study that the matrix tablets of  
metoprolol succinate prepared using xanthan gum  and hydroxylpropyl methyl 
cellulose can be successfully employed as once a day oral drug delivery 
system.Important formulation factors were systematically studied for the 
development of modified release tablets of metaprolol succinate. It is possible to 
fabricate modified release tablets of  metoprolol succinate using xanthan gum and 
hydroxyl propyl methyl cellulose. The combination of matrixing  agents namely 
xanthan gum and HPMC overcomes disadvantages of each polymer. The intial drug  
burst release was controlled by quick gelation of xanthan gum whereas subsequent 
drug release and matrix integrity were maintained by firm gel of HPMC. The 
economy of  xanthan gum may help the formulator to decrease the cost of the 
fabricated product  
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